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Abstract 
Stigma is a complex phenomenon with a myriad of detrimental health and social impacts that are 
not fully studied or understood. Persistent stigma exists towards individuals who have opioid use 
disorder (OUD) in British Columbia. OUD is a chronic, relapsing, clinical condition that has 
been identified as one of the most challenging substance use disorders. For those affected, they 
must also endure the consequences of stigma that promote barriers to health care, health and 
social inequalities, diminished quality of life as well as increased morbidity and mortality. The 
current unremitting opioid overdose crisis in British Columbia further emphasizes the 
importance of eradicating stigma towards individuals who use opioids and/or suffer from OUD, 
as untreated OUD is fueling this multifaceted public health emergency. For these reasons, an 
integrative literature review has been conducted to identify how primary care providers in British 
Columbia can address the intersecting stigmas for individuals suffering OUD. The results are 
discussed within the context of primary health care in British Columbia. Whittemore and Knafl’s 
approach to the integrative literature review was utilized in this study to review eleven pertinent 
articles. The findings suggest that stigma occurs on varying levels for individuals with OUD that 
serve to reinforce each other and manifest as discrimination, mistrust, social distancing, 
minimized advocacy, unequal access to health care and suboptimal health care. Further, the 
findings indicated that the role of primary care providers may be instrumental in eradicating 
stigma in a timely manner. Recommendations for primary care providers to dismantle the stigma 
associated with OUD are discussed, and specific strategies for the primary care setting are 
presented.  
 Keywords: Opioid use disorder, stigma, discrimination, primary health care, primary care 
provider 
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Glossary of Terms 
 
Analogue: a chemical that is similar in structure to another chemical and shares similar effects on 
the body as the original chemical.  
 
Analgesia: loss of sensation of pain resulting from an interruption in the nervous system pathway 
between the sensory system and brain.  
 
Criminalization: act of making an action criminal by making it illegal. Can also refer to treating 
an individual or a group of individuals as criminals if they are associated or found to be 
engaging in an illegal activity.  
 
Decriminalization: removal of an action or behaviour from the scope of the criminal justice 
system. In drug policy, refers to a spectrum of approaches that remove criminal sanctions 
associated with drug possession.  
 
Discrimination: unjust, unequal, different or prejudicial treatment of an individual or group of 
individuals based on characteristics such as mental illness, race, sex or age. Withholds or 
limits access to opportunities, benefits, and advantages available to other members of 
society. 
 
Diversion: any non-intended or non-medical use a prescription opioid or use by any individual 
other than the individual it was prescribed.  
 
Harm Reduction: policies and programs that aim to minimize immediate health, social and 
economic harms associated with the use of psychoactive substances, without necessary 
requiring a goal of abstinence or a decrease in substance use. Examples include reduced 
transmission of infectious diseases and overdose mortality by needle and syringe 
exchange programs and supervised injection or consumption services.  
 
Illegal Opioid: illegally manufactured opioids that are not subjected to regulations or quality 
control measures and are typically mixed (or ‘cut’) with potentially harmful substances 
and contaminants to increase volume and profit in illegal drug market. Common 
examples are street heroin, fentanyl, carfentanil, morphine, and oxycodone. May also be 
in the form of counterfeit tablets pressed to look like pharmaceutical grade opioids. 
 
Marginalization: treatment of individuals or groups as insignificant or peripheralized on the basis 
of their identities, associations, experiences, and environments. 
 
Misuse: the use of a medication for nonmedical purposes or for other reasons other than 
prescribed. Misuse can be willful or unintentional use in a manner not consistent with 
medical guidelines, such as altering dosing or sharing prescription opioids which may 
have harmful consequences. 
  
Opiate: compounds naturally derived from juice of opium poppies, for example morphine.  
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Opioid: any substance with the ability to bind to opioid receptors and alter neural signal 
transmission, suppressing ability to feel pain. At higher doses, opioids cause feelings of 
euphoria and respiratory depression. Opioids may be prescribed or obtained illegally and 
can be blocked by opioid receptor antagonists such as naloxone. Opioids can be synthetic 
(fentanyl), semi-synthetic (hydromorphone) or naturally derived (morphine). Opioids can 
be consumed via ingestion, inhalation, transdermal delivery, or subcutaneous, 
intramuscular or intravenous injection.  
 
Opioid Agonist: any substance that binds to and activates opioid receptors, providing relief from 
withdrawal symptoms and cravings for individuals with opioid use disorder and pain 
relief if used for pain management.  
 
Opioid Agonist Treatment: evidence-based treatment for opioid use disorder, which includes 
administration of opioid agonists to alleviate withdrawal symptoms. Part of a 
comprehensive treatment plan for opioid use disorder, which also includes psychological 
and social support. 
 
Opioid Antagonist: a substance that binds to opioid receptors and blocks the receptor, preventing 
the body from responding to opioids. For example, naloxone may be used as an 
intramuscular injection to rapidly displace opioid agonists from receptors in an opioid 
overdose situation.  
 
Opioid Receptor: the site within the central and peripheral nervous systems that opioids bind to 
producing their effects.  
 
Opioid Use Disorder: a chronic, relapsing condition characterized by at least two symptoms 
listed in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for 
opioid use disorder. This includes taking opioids in amounts larger or longer than 
intended, craving or strong desire to use opioids, and persistent desire or unsuccessful 
efforts to cut down or control opioid use.  
 
People First Language: humanizing terminology that acknowledges someone as a person before 
describing their personal attributes or health conditions. It does not identify people by 
secondary or incidental qualities or conditions. For example: instead of ‘opioid addict’ 
use ‘person with opioid use disorder’. 
 
Primary Care: typically, the initial point of contact between a patient and a health care 
professional where the majority of non-acute health problems are treated, ideally 
providing continuity, integration of health care services and/or referral to specialists.  
 
Primary Care Provider: health care professional, usually a general practitioner physician or nurse 
practitioner, who provides primary care.  
 
Primary Health Care: a broader term that includes primary care; refers to a comprehensive, 
universally accessible spectrum of health care that focus on patient centered care and 
provides diagnostic, curative, rehabilitative, supportive and palliative services. Population 
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based approaches are also employed to promote health and prevent illness and injury. All 
determinants of health are addressed in this model.  
 
Social Determinant of Health: conditions in the environments in which people are born, live, 
learn, work, play, and age. Includes factors such as socioeconomic status, education, 
neighbourhood and physical environment, employment, social supports, healthy 
behaviours, and access to health care.  
 
Stereotype: over-generalized belief about a particular category of individuals, an expectation that 
people might have about every person of a particular group. 
 
Trauma Informed Care: provision of health care that is sensitive to the effects of trauma and 
works to avoid re-traumatization. Ensures safety, trust, choice, collaboration and building 
on strengths and skills
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Chapter I: Introduction 
The World Health Organization has identified that illegally obtained substance use 
disorders are the number one stigmatized condition amongst several frequently stigmatized 
social issues, including criminal activity (Kelly et al., 2016). Canada is reflective of this, with 
substance use disorders recognized as the most highly stigmatized health condition, with 
damaging impacts that are understudied and not fully understood (Kelly et al., 2016; Khenti et 
al., 2019; Kulesza et al., 2017). Traditionally, stigma associated with drug use was thought to 
serve as a deterrent for use, but it is increasingly apparent that the stigmatization of people who 
use drugs has ultimately led to poorer health outcomes and is therefore closely related to the 
determinants of health. The tendency of strong moral and criminal justice views surrounding 
drug use disorders have overshadowed their legitimacy as a medical illness, creating a unique 
stigma and divide from other health conditions (Stuart, 2019). 
Currently, an escalating opioid crisis exists across Canada, with almost 4000 opioid 
related deaths in 2017, most involving illegal opioid analogues (Korowynk et al., 2019). In 
British Columbia, the monthly drug overdose death toll stubbornly persists above historical 
averages despite a declared public health emergency in 2016, and upscaled harm reduction 
services (Tyndall, 2018). Untreated opioid use disorder (OUD) is fueling this crisis and both 
public and professional stigma have been recognized as barriers to delivering optimal care and 
evidenced based treatment to individuals with OUD (British Columbia, 2016). The associated 
stigma may contribute to delaying appropriate help-seeking behaviors or the termination of 
treatment for a treatable problem (Goodyear et al., 2018). Further, the ongoing heightened 
awareness of opioid use may be fostering an unintended consequence of perpetuating the 
associated stigma. This stigma persists as OUD is perceived as a ‘choice’ whereby affected 
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individuals are capable of exercising control over their opioid use (Kelly et al., 2016). This 
perception has translated into a lack of support from the public for harm reduction activities, as 
well as the continued use of damaging labels for people who use substances, including ‘abuser’, 
‘addict’, ‘drug seeker’, or ‘junkie’, terms which reinforce existing barriers. Additionally, the 
medical diagnosis of ‘opioid addiction’ inflicts an individual with higher responsibility for their 
disease and supports the perception of their opioid use as voluntary behaviour (Goodyear et al., 
2018). For these reasons, this paper will exclude the use of such pejorative terms in efforts to 
ensure this work does not enhance or add to stigma for those suffering OUD by any means. 
These negative attitudes are a major source of stress as well as an immense disadvantage for 
those who are stigmatized, as evidenced by population health inequities across multiple social 
and physical health domains (Hatzenbuehler et al., 2013; Tsai et al., 2019).  
In 2016, the Canadian Medical Association and Canadian Psychiatric Association gave a 
joint key recommendation to promote equal access to health care, treatment, and recovery for 
those with mental health and substance use disorders that articulated the identification and 
elimination of stigma within health care systems (Khenti et al., 2019). Furthermore, the British 
Columbia Provincial Health Officer has also made it a provincial priority to de-stigmatize people 
who use drugs in response to the unremitting opioid overdose crisis, as up to four British 
Columbians per day continue to die from a preventable overdose (Office of the Provincial Health 
Officer, 2019). In spite of these appeals for change, it has proven difficult to stop stigma 
altogether and it continues to persist within the British Columbia health care system. This is 
particularly problematic given that accessible care for individuals with OUD is scarce and 
effective treatment options for OUD, while available, are underutilized (Office of the Provincial 
Health Officer, 2019; Stuart, 2019). Most often the first point of contact for those seeking help 
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with a substance use disorder is in primary care and evidence has strongly recommended that 
patients with OUD are best managed in supportive primary care practices, similarly to other 
chronic diseases (Korowynk et al., 2019). For this reason, it is vital that primary care providers in 
British Columbia are well informed of the immense and devastating impacts of stigma, 
especially when it may be intentionally or inadvertently inhibiting access to services for those 
struggling with OUD. The purpose of this integrated literature review is to answer the clinical 
query: What are the impacts when primary care providers diminish stigma for patients with 
opioid use disorder in British Columbia? 
In this paper I will provide background on the concept of stigma, its origin, evolving 
definition, interrelated concepts, how it can be experienced, its relevance to individuals with 
OUD and primary care providers in British Columbia. I will then review opioids and their use in 
British Columbia, the diagnosis of OUD, evidence-based OUD treatment and the relevance of 
this to primary care providers in British Columbia. The paper will also then discuss the local 
impacts of stigma in the province’s primary health care settings and how this is enforcing 
barriers to optimal care for individuals with OUD. Additionally, the approach to the search for 
relevant literature to answer the clinical question will be described, followed by a critical 
analysis of the chosen relevant literature. A discussion of the findings will inform primary care 
providers of British Columbia of the varying sources of stigma and their capabilities to diminish 
it through evidence-based practices to improve treatment access, engagement and retention for 
individuals with OUD. In conclusion, the limitations of this paper will be addressed and 
considerations for future research will be recommended.  
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Chapter II: Background and Context 
 This chapter of the paper will provide background on the concept of stigma, the context 
of primary health care in British Columbia, the use of opioids, and the relevance of stigma in 
primary care for patients with OUD in British Columbia. Thorough descriptions of the variables 
of interest will provide necessary context to facilitate the subsequent stages of the review. By 
encompassing these related variables, the problem the integrative literature review aims to 
address will be clearly identified, while rationalizing the purpose of the review (Whittemore & 
Knafl, 2005). 
History of Stigma 
 
Stigma is a complex phenomenon, as such varying definitions have been described within 
the literature. The term originated in ancient Greece and referred to bodily signs made using cuts 
or burns into the body meant to expose something unusual and bad about the moral status of the 
bearer (Goffman, 1963). Through the use of this visual aid, slaves, criminals, or traitors were 
then publicised as blemished persons, who were to be avoided, especially in public places 
(Goffman, 1963). In the 1950s, social psychologists recognized stigma as a situation where an 
individual is “disqualified from full social acceptance” (Goffman, 1963, p. 5). Alternative and 
elaborate conceptual definitions are found within the literature since the late sociologist Erving 
Goffman inspired further research after publishing in 1963 on the nature, sources, and 
consequences of stigma. He referred to the term as “an attribute that is deeply discrediting” 
(Goffman, 1963, p. 13), reducing a whole person to a tainted or discounted one. Ongoing 
research contributions related to stigma have been multidisciplinary in origin since the concept 
can be applied to a wide array of unique circumstances. This has allowed differing descriptions 
of its conceptualization; however, large overlap exists across disciplines (Link & Phelan, 2001). 
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It is important to note that despite the ongoing refinements and varying definitions, the negative 
impacts of stigma are repeatedly demonstrated on the lives of those who are stigmatized.  
In Goffman’s (1963) work, he recognizes and provides a definition of stigma as it relates 
to social constructs. He acknowledges that individuals tend to mindlessly create an anticipation 
of normative expectations of how individuals or strangers should be and, subsequently, their 
probable expectations of the person’s attributes are either fulfilled or not fulfilled (Goffman, 
1963). This concept relates heavily to the social identities that are established by society: if the 
expectations of the anticipated identity are met or if there are attributes that make the individual 
different from their available categories in a less desirable manner, this person then becomes 
reduced and has the attribute of stigma (Goffman, 1963). Goffman (1963) suggests those 
attributes that create stigma should be considered in the way they relate to the manner of 
relationships between individuals as well as how they are associated with the social settings that 
establish categories of people likely to be encountered there. A stigmatizing attribute to one 
person may be a usual, expected feature of another and, for this reason, it is neither creditable nor 
discreditable to be a stigmatizing attribute (Goffman, 1963). A stigma is then “really a special 
kind of relationship between attribute and stereotype” (Goffman, 1963, p. 14). 
The alternative definitions of stigma after Goffman’s publication continue to significantly 
relate to social interaction. Stafford & Scott (1986) proposed that stigma “is a characteristic of 
persons that is contrary to a norm of a social unit” (as cited in Link & Phelan, 2001, p. 364). A 
norm is the “shared belief that a person ought to behave in a certain way at a certain time” (Link 
& Phelan, 2001, p. 365). Another influential definition that relates to Goffman’s work around 
social structure is that stigma is the relationship between a mark or attribute that links a person to 
undesirable characteristics or stereotypes (Link & Phelan, 2001). Stigmatization is also said to 
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occur when a person possesses (or is believed to possess) an “attribute or characteristic that 
conveys a social identity that is devalued in a particular social context” (Major & O’Brien, 
2005). These definitions seem to agree that those who are stigmatized have, or are suspected to 
have, a feature that indicates them as different or incongruous, which causes them to be devalued 
from the perspective of others. These evaluations are then widely shared amongst the members 
of a common group or culture and develop the basis for excluding or avoiding individuals of the 
stereotyped category (Major & O’Brien, 2005). The stigmatizing attribute can be visible or 
invisible, controllable or uncontrollable, and may be linked to appearance, behaviours, or a group 
membership (Major & O’Brien, 2005). Examples include a physical deformity, illegal substance 
use, or race. These examples reinforce that stigma within a socially constructed definition is 
relationship- and context-specific and not vested within a person, but that these discrediting 
attributes are found almost everywhere in society (Major & O’Brien, 2005; Goffman, 1963). 
Link and Phelan chose to define stigma as a convergence of interrelated components: 
“stigma exists when elements of labeling, stereotyping, separation, status loss, and 
discrimination occur together in a power situation that allows them” (2001, p. 377). Through the 
linking of behaviours and social elements, this definition is lengthier and more complex, but the 
authors recognize their definition has been derived with specific goals in mind, including its 
coherence when applied to groups that are referred to as stigmatized groups (Link & Phelan, 
2001). The authors argue that for stigmatization to occur, power must be exercised and can occur 
in social, economic, and political domains (Link & Phelan, 2001).  
Stigma is a complex issue and the classic definitions related to social constructs may not 
be suitable for all individuals, groups, or cultures (Mannarini, & Rossi, 2019; Weiss et al., 2006). 
Stigma that is based on normalcy and a deviance of this is an inadequate and inappropriate 
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definition for current society for several reasons. It is an unacceptable fit for policy making, 
particularly given the multiculturalism that exists in British Columbia, and especially in 
situations when powerful and powerless groups negatively evaluate the other; furthermore, 
because the powerful group controls access to resources, their beliefs are likely to prevail and 
their version of normal may be in opposition to that of the powerless (Major & O’Brien, 2005). 
It is also recognized within the literature that the social process of stigma can be 
experienced, anticipated, perceived, and internalized differently by individuals (Weiss et al., 
2006; Yang et al., 2019). The controllability, concealability, and entitativity characteristics of 
stigma influence the psychological and behavioural reactions to those stigmas (Major & O’Brien, 
2005). Understanding these varying perspectives and their relative subjective nature is necessary 
when considering the concept of stigma. There is potential that a stigmatized individual is fully 
aware that their differentness is evident and therefore this individual is experiencing the 
difficulty of being discredited; or perhaps this individual may have the assumption that the 
stigmatizing attribute is not known about, or immediately perceivable, causing them to anticipate 
the potential of being discredited (Goffman, 1963). This is an important difference and is 
contextual for the individual and their environment, even though a “stigmatized individual is 
likely to have experience with both situations” (Goffman, 1963, p. 14). These situations relate to 
stigma that may be occurring at either the public or individual level, or both. Public stigma is the 
pervasive, negative perceptions and beliefs of the public toward a group or a person (Goodyear et 
al., 2018). The process of self-stigma or internalized stigma is when a stigmatized individual 
applies a negative stereotype to themselves that relates to the negative stereotypes of the 
stigmatized group they are associated with, which may produce feelings of self-devaluation and 
worthlessness (Kulesza et al., 2017).  
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Consequences of Stigma 
 
The consequences of a concept are the resulting outcomes after it has occurred 
(Nuopponen, 2010). It is not possible to assess the full extent of the vast impacts of 
stigmatization here; however, the literature indicates the consequences are significantly negative 
to an individual’s life. The effects can include social disadvantage, status loss, identity threat, 
diminished empowerment, loss of self-esteem, unpleasant personal experiences, social isolation, 
maladaptive coping mechanisms, avoidance of help seeking behaviour, increased psychological 
and physiological stress, poor health outcomes, discrimination, stereotyping, and victimization 
(Al-Khouja & Corrigan, 2017; Hatzenbuehler et al., 2013; Link & Phelan, 2001; Major & 
O’Brien, 2005; Weiss et al., 2006; Stangl et al., 2019). The results of these outcomes likely affect 
a person’s earnings, housing, criminal involvement, health, and life itself (Link & Phelan, 2001). 
It is also suggested stigma may be a major contributor to morbidity and mortality at a population 
level (Hatzenbuehler et al., 2013). Subsequently, stigma can be linked closely to the social 
determinants of health in that it has myriad detrimental impacts on the wellness of those it affects 
by undermining and impeding social relationships, resource availability, stress, and 
psychological responses, thereby exacerbating poor health (Stangl et al., 2019). 
Associated Concepts and Definition 
 
Stigma is described as a multidimensional construct, a convergence of interrelated 
components (Link & Phelan, 2001; Major & O’Brien, 2005). Several attributes of stigma that co-
occur include: exclusion, rejection, blame, labeling, stereotyping, negative belief, separation, 
deviance, status loss, social disqualification, social disadvantage, prejudice, discrimination, 
marginalization, as well as low social status and power (Weiss et al., 2006; Link & Phelan, 2001; 
Major & O’Brien, 2005; Goodyear et al., 2018; Hatzenbuehler et al., 2013).  
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In more recent conceptualizations of the literature, discrimination is often considered a 
constitutive feature of stigma. Authors argue that stigma cannot hold the meaning it is commonly 
assigned when discrimination is not included in the definition (Hatzenbuehler, et al., 2013). 
Varieties of discrimination can occur; for instance, at the individual and structural level, 
discrimination can manifest as unequal treatment that arises from membership in a particular 
group or societal limitations that cause loss of life opportunities, resources, and well-being 
(Hatzenbuehler, et al., 2013). The overall stigma process incorporates many more elements, and, 
for this reason, the concept of stigma is applied in a broader sense than discrimination 
(Hatzenbuehler et al., 2013). 
Marginalized is a concept that is widely used within social sciences as a descriptor of 
people, locations, or events and provides a vague sense of disadvantage and injustice (Vasas, 
2005). Marginalization refers to individuals or groups who are peripheralized on the basis of 
their identities, associations, experiences, and environments (Vasas, 2005). As such, it is easily 
relatable to the concept of stigma as both marginalized and stigmatized populations are socially 
excluded and experience inequalities in the distribution of resources and power (Vasas, 2005). 
The connection between these two concepts likely lies within the interplay of power and how it 
is used, but marginalization refers more to the process used to explore the factors that create, 
define, maintain, and enforce the margins that exist (Vasas, 2005). It has also been identified that 
stigma prevents those who are marginalized from accessing resources and vulnerability to health 
problems because they are often identified with intersecting stigmas, such as substance use, 
poverty, ethnicity, and sexual preferences (Stangl et al., 2019).  
The definition of stigma that I have derived from the literature to encompass the 
complexity of impacts affecting individuals with OUD in British Columbia is as follows: Stigma 
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is a set of negative attitudes such as prejudice or discrimination about an individual or group of 
individuals due to a certain behaviour (opioid use) and/or life circumstances that promotes 
marginalization. It can originate from external or internal sources with the influence of a power 
differential and may manifest on varying levels such as interpersonally (the language used to 
speak to someone) or sociostructurally (organization of health care services). Within health care, 
stigma results in barriers accessing care, decreased acceptability, adherence to treatment, 
resiliency, and advocacy. The organizational outcomes impact the availability and quality of 
care, laws, policies, media, and social protection. Stigma fuels health and social inequalities by 
fostering social exclusion, decreased quality of life and increased morbidity and mortality. 
Impacts of Stigma in Primary Health Care in British Columbia  
 
Primary care is typically the initial point of contact between a patient and the health care 
system and refers to health related services that are provided within the community setting. 
Primary health care is a broader term that is inclusive of primary care but encompasses patient 
centered care and a spectrum of comprehensive health services while including population-based 
approaches to address health promotion, community development and acknowledgment of the 
determinants of health (Hutchison et al., 2011). Another chief aim of primary health care is to 
improve access to care whilst responding to the needs of the patient and community (Hutchison 
et al., 2011). Within British Columbia, the majority of primary care is provided by general 
practitioners including family physicians and nurse practitioners. Nurse practitioners (NPs) are 
registered nurses with master’s level education who “…autonomously diagnose, treat and 
manage acute and chronic physical and mental illnesses” (The British Columbia College of 
Nurses and Midwives [BCCNM] 2020, p. 5) within a holistic model of care. NP’s scope of 
practice includes ordering and interpreting tests, prescribing medications, and performing 
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medical procedures (British Columbia, 2018). It is the expectation of NPs to develop knowledge 
and skills to effectively address current issues in practice, and the provision of care for patients 
with substance use disorders has been articulated as an entry level competency (BCCNM, 2017). 
A large development in their role has occurred over the last two years with the provincial 
government investing in more education seats and increasing available positions as an action to 
increase access to care and help shift primary care to a team-based primary health care system 
(British Columbia, 2018). Additionally, an amendment of the Controlled Drugs and Substances 
Act took place in 2018, enabling NPs to prescribe opioid agonist treatment (OAT), an evidence-
based therapy for OUD (S.C. 1996, c. 19). In this paper the term primary care provider will be 
used as an inclusive term that reflects both family physicians and nurse practitioners. 
A core value of Canadian society is appropriate access to medical care, equally available 
to all patients, including those belonging to vulnerable and marginalized populations such as 
those suffering with OUD (Martin et al., 2018). Currently, health care services for mild and 
moderate cases of OUD can be appropriately delivered in primary health care and for those who 
necessitate a higher level of care, links to specialized services should be implemented (British 
Columbia Center on Substance Use and British Columbia Ministry of Health [BCCSU & 
BCMOH], 2017). The British Columbia Ministry of Mental Health and Addictions has further 
promoted integrating a primary health care model to provide a network of seamless, coordinated 
services specific to mental health and substance use disorders, inclusive of all citizens (British 
Columbia, 2020). Interestingly, the provincial government chose the stigmatizing term 
‘addiction’ in the naming of the ministry. Although ‘addiction’ is indeed a medical diagnosis, it 
is also a highly stigmatizing term and there are arguments for avoiding its use (Kennedy-
Hendricks et al., 2017; Collins et al., 2018).  
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An increased prevalence of mental health and substance use issues compared to the rest 
of Canada substantiated the new ministry in 2017, and their first project involved defining the 
existing problematic areas in the state of health care (British Columbia, 2020). An urgent 
concern identified was the persistent systematic barriers to health care for individuals with 
substance use disorders, which included prevalent stigma (British Columbia, 2020). Stigma was 
reported occurring often in the form of discrimination from health care providers (British 
Columbia, 2020). This is a substantial barrier that prevents individuals in British Columbia with 
OUD from seeking help, for fear of what a health care provider may think or say, causing them 
to avoid getting the care they need until their condition has deteriorated, likely then requiring a 
higher level of care. Further, for those individuals who suffer longer periods of time, more 
extensive treatments and extended recovery time are likely (British Columbia, 2020). 
Currently, not all primary care providers in British Columbia have received training 
focused on OUDs in the same way that they have been trained in other areas of medicine, which 
endorses professional stigma in provision of care for this vulnerable population. This knowledge 
gap and limited training may diminish OUD as a legitimate, complex, chronic medical condition 
and prevents primary care providers to optimize their scope of practice to provide treatment for 
patients with OUD related health problems. Due to the large geographical span of British 
Columbia, primary care providers in rural and remote areas face increasingly limited substance 
use specialist support, therefore heightening barriers for patients to obtain evidence-based care, 
further complicating the situation (British Columbia, 2020). Consequently, the inconsistent 
inclusion of patients with OUD in primary care settings prevents equality in access to care while 
diminishing engagement, retention, and collaboration in care efforts. Further, patient centered 
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care as well as recovery and healing processes are inhibited due to fragmented coordination of 
services. 
A recent province wide harm reduction client survey further concluded that individuals 
who use substances continue to confront structural barriers and stigma, limiting their initiation of 
evidence-based treatment and retention in treatment (Graham et al., 2019). The main barrier 
identified to accessing OAT was difficulty locating a prescriber, a finding which verifies the 
notion that there is limited uptake of OAT and OUD care within the province’s primary care 
settings (Graham et al., 2019). Current federal guidelines recommend patients with OUD have 
improved outcomes when accessing services from primary care (Korowynk et al., 2019). 
Improved treatment adherence, avoidance of illegally purchased opioids, and higher patient 
satisfaction have been reported when care was administered by primary care programs rather 
than a clinic focusing on OUD (Korowynk et al., 2019). This distinction is pertinent given that 
the demand for OUD care in British Columbia far exceeds the availability of specialized 
substance use specialist care. Furthermore, collaborative primary care models have been 
effective in improving the management of other chronic diseases and therefore the opportunity to 
implement the same standard of care for OUD would likely not only enhance clinical outcomes, 
but also decrease the stigma associated with OUD treatment (Alford et al., 2011). In addition, 
office-based treatment is well suited to best manage OUD in British Columbia due to relative 
location abundance, geographic dispersion, and the absence of stigma associated with opioid use 
speciality centers (Livingston et al., 2018).  
Professional and Ethical Standards of Primary Care Providers 
 
The British Columbia Human Rights Code prohibits discrimination in the provision of 
health care services to protect individuals who may be actual or perceived members of certain 
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groups, including those with a physical or mental disability (RSBC 1996, c. 210). Additionally, 
primary care providers in the province have an obligation to abide by their code of ethics and 
professional practice standards through their applicable regulatory body; the College of 
Physicians and Surgeons of British Columbia for family physicians, and The British Columbia 
College of Nurses and Midwives (BCCNM) as well as the Canadian Nurses Association for NPs. 
These professional responsibilities delineate that all individuals of society, including those who 
have complex medical conditions, difficulty complying with recommended medical treatments 
as a consequence of an active substance use disorder, involvement in the criminal justice system, 
or social problems are equally deserving of accessing respectful health care, even if this requires 
necessary extra time (CPSBC, 2019a; Canadian Nurses Association [CNA], 2017). It would be a 
violation of the primary care provider’s ethical principles to refuse to treat a patient in such 
circumstances (CPSBC, 2019a; CNA, 2017). Providing exemplary ethical care involves 
compassion and prudency to recognize those who are suffering or vulnerable and seeks to 
understand their unique circumstances, while advocating to improve their quality of life and 
overcome barriers to health care (CNA, 2017).  
Primary care providers must also identify the impacts of their personal values, beliefs and 
experiences to recognize potential conflicts in their provision of care to patients with OUD 
(BCCNM, 2018). In the event that a primary care provider makes a personal choice to not 
provide a certain treatment or procedure, it is an expectation that they provide an alternate health 
care provider to meet the individuals’ needs or desires, and must not abandon the patient (CNA, 
2017). Within the province, patients with OUD should feel welcomed, respected and safe when 
accessing care from a primary care provider, free of stigma or discrimination. 
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A Model Case of Stigma Related to Opioid Use Disorder 
 
 A model case that represents a real-life example of the concept of stigma that includes its 
critical attributes will be presented here. This example will be presented in four stages as it 
relates to OUD: aware, agree, apply, and harm (Al-Khouja & Corrigan, 2017). Individuals with 
OUD are aware of stereotypes such as “People who are heroin junkies are dangerous” 
contributing to how the individual perceives this stigma. Those who agree with the stereotype: 
“Yes, that’s right, I think heroin junkies are dangerous” exhibit public stigma. Self-stigma occurs 
when the individual with OUD applies the stereotype to themselves: “I’m a junkie so I am 
dangerous.” Lastly, people are then harmed by stereotypes due to diminished self-value: “I think 
I’m a bad person when I realize I’m a heroin user who is dangerous” (Al-Khouja & Corrigan, 
2017). This then can lead to a ‘why-try?’ phenomenon: “Why should I try to get help for my 
heroin problem; someone like me is only going to fail” due to a devalued identity, rejection, 
labeling, discrimination, loss of empowerment, and diminished self-esteem (Al-Khouja & 
Corrigan, 2017; Kulesza et al., 2017). 
Mechanism of Opioids 
 
For centuries, the extracts of opium poppies have been used medicinally and socially to 
produce analgesia, euphoria, sleep, and to prevent diarrhea (Rang et al., 2016). These powerful 
physiological effects are due to the opiate morphine and other related compounds contained in 
the juice of the poppy (Rang et al., 2016). Since its chemical structure was determined in 1902, 
morphine has been subsequently reproduced and modified to form several semisynthetic and 
fully synthetic products called opioids (Rang et al., 2016). Opioids are any substance with the 
ability to bind to the body’s opioid receptors and alter neural signal transmission, resulting in 
pain relief and feelings of euphoria (Mistry et al., 2014). The receptors are widely distributed 
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throughout the central and peripheral nervous systems with variable opioid binding affinities, 
specificity and efficacy (Mistry et al., 2014). After repeated opioid use over time, an increase in 
the amount of opioid needed to produce the desired effect may develop and this is known as 
opioid tolerance (Rang et al., 2016). Opioid tolerance is attributed to desensitization of the opioid 
receptors and other adaptive changes that occur at the cellular level (Rang et al., 2016). In the 
event that an opioid is abruptly stopped after repeated use or an opioid receptor antagonist such 
as naloxone is introduced, physical opioid dependence may become evident by a withdrawal 
syndrome that is characterized by increased irritability, diarrhea, weight loss, body shakes, 
writhing, restlessness, shivering, runny nose and goose bumps (Rang et al., 2016).  
The elicited euphoria, powerful sense of contentment and well-being associated with 
opioid use at higher doses is related to a release of dopamine that stimulates the reward pathway 
of the brain and positively reinforces the pleasurable feelings (Mistry et al., 2014). The 
dopaminergic surge has been attributed to the mechanism of forming a psychological opioid 
dependence, as individuals tend to want to repeat this satisfying experience (Mistry et al., 2014). 
Natural reward pathways serve to perpetuate beneficial actions such as seeking food, but in the 
case of opioid use, it is hypothesized the repetitive reward sensation motivates adaptive 
behaviours to transition from voluntary opioid use to habitual use, and eventually compulsive use 
(Mistry et al., 2014). The dopamine pathways maintain seeking and using opioids and may 
ultimately lead to a loss of control over behaviour and impair decision making (Mistry et al., 
2014). Due to the principle of tolerance, gradually higher opioid doses are necessary to replicate 
the same euphoria and eventually with continual use, individuals will reach a point where they 
must use opioids to avoid withdrawal. In spite of this, psychological dependence rarely occurs 
when an opioid is given to patients for analgesic purposes (Rang et al., 2016). 
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Inter-individual variability how a person may respond to opioids and their adverse side 
effects can be due to altered metabolism or genetic variants of dopamine and opioid receptor 
sensitivity (Mistry et al., 2014; Rang et al., 2016). Thus, it is hypothesized genetic susceptibility 
may contribute to a person’s risk for forming OUD; however, there are no clear patterns of 
inheritance and non-genetic factors are also critical extrinsic variables influencing this complex 
disorder (Mistry et al., 2014). The extensive study of opioids remains ongoing to better 
understand their powerful effects and to develop alternative analgesics due to the risk of forming 
OUD as well as a myriad of adverse reactions: fatal and non-fatal overdose, respiratory 
depression, nausea, vomiting, constipation, bronchoconstriction, low blood pressure, sedation, 
dizziness, and slow heart rate (Rang et al., 2016; Canadian Pharmacists Association, 2020).  
Prescription Opioids in British Columbia 
 
Currently in British Columbia, prescription opioids can be obtained from a qualified 
prescriber, such as a primary care provider, or opioids can be illegally purchased from an 
unregulated drug market (Bruneau et al., 2018). Prescription opioids are pharmaceutical grade 
medications that are manufactured by licensed and regulated pharmaceutical companies to be 
dispensed from pharmacies (Canadian Research Initiative in Substance Misuse [CRISM], n.d.). 
These medications are most often prescribed for their analgesic properties to treat and prevent 
acute pain, chronic non-cancer pain and cancer pain, but they are generally reserved for pain that 
does not respond well to other treatment options due to their high-risk profile (Canadian 
Pharmacists Association, 2020). Other clinical indications for the use of opioids exist such as 
codeine for treatment of non-productive cough and morphine to help manage dyspnea in cancer 
patients (Canadian Pharmacists Association, 2020).  
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Prescribing opioids comes with serious warnings and precautions from the Canadian 
Pharmacists Association and Health Canada, as opioid use can result in non-medical use as well 
as fatal and nonfatal overdose (2020). Opioid prescribers are recommended to use the lowest 
effective dose for the shortest duration to avoid adverse side effects and to help control the 
amount of opioid medications in the community, as excessive prescribing may expose patients to 
more chronic use and unused opioid medication may be stolen or diverted for non-medical use 
(CPSBC, 2019b). This is demonstrated by an increase in the prescribing of opioids over the last 
20 years within North America that correlates with substantial increases in opioid-related 
mortality rates and OUD (Kennedy-Hendricks et al., 2016). This increase in prescribing can be 
attributed to liberal standards of practice for managing pain control with opioids, limited 
treatment options for chronic pain, the view of these medications as safe for chronic pain 
management, availability of high potency oral tablet formulations, in addition to pharmaceutical 
companies’ targeted marketing to promote opioid prescribing with minimized risk of forming 
OUD (Antoniou et al., 2019; Goodyear et al., 2018; Jones et al., 2018).  
In 2017, an updated Canadian clinical practice guideline on the use of opioids for the 
management of chronic noncancer pain encouraged tapering opioid doses in individuals already 
receiving these drugs, recommended the use of non-opioid alternatives, and suggested 
restrictions on maximum prescribed doses (Antoniou et al., 2019). These changes were in 
addition to governing bodies removing long acting formulations of high strength opioids from 
drug benefit programs (Antoniou et al., 2019). Despite these initiatives and a decrease in the 
volume of opioids prescribed, opioid related deaths remain elevated in Canada, which may be 
accounted for by the fact that the illegal alternatives are lethal in the present environment 
(Antoniou et al., 2019; Tyndall, 2018). These elevated figures speak to a substantial unintended 
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consequence of opioid deprescribing for those individuals who once had a supply of prescribed 
or diverted pharmaceutical opioids: they must now resort to a purchase from an unregulated drug 
market that may be fatal (Tyndall, 2018). 
Unregulated Drug Supply in British Columbia 
 
Opioids that are purchased illegally in British Columbia can be either diverted 
prescription opioids for nonmedical use or illegally manufactured opioids (Bruneau et al., 2018). 
As illegally manufactured opioids are not subjected to any quality control measures, they are 
often mixed with other substances or contaminants to increase their volume and therefore street 
value, which is potentially harmful and unbeknownst to the user (CRISM, n.d.). Common 
examples of these are street heroin, fentanyl, morphine, and oxycodone (CRISM, n.d.). Illegal 
opioids can also be found in the form of counterfeit tablets forged to look pharmaceutical grade 
opioids, which again, poses harmful risks to the user (CRISM, n.d.). Within British Columbia, 
the supply of illegal, unregulated opioids has become displaced with highly potent synthetic 
opioids, namely fentanyl and carfentanil (Office of the Provincial Health Officer, 2019). 
Fentanyl is currently prescribed effectively in clinical settings as a medication to treat breath-
through pain related to cancer and for post-operative surgical pain due it is high potency and 
rapid onset of action (Han et al., 2019). Given the narrow range between therapeutic and lethal 
doses of fentanyl, it poses high risk of overdose, especially in the unregulated drug market when 
combined in unknown amounts with other opioids such as heroin (Han et al., 2019). Fentanyl has 
a potency of action 20 to 40 times higher than heroin and is thought to be imported from 
overseas to be sold as heroin or opioid tablets (British Columbia Centre for Disease Control 
[BCCDC], 2016).  
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The presence of these contaminants in the illegal drug supply became evident in 2016 
when British Columbia experienced a rapid spike of unintentional drug overdoses and an 
estimated 967 overdose deaths (CRISM, n.d.). Fentanyl was detected in approximately 62% of 
those deaths, a 281% increase in overdose deaths involving fentanyl compared to the prior year 
(BCCSU & BCMOH, 2017). This necessitated a declared public health emergency, while also 
exposing gaps within the health care system for adequate care provision for individuals with 
OUD (Tyndall, 2018). Opioid-related deaths continue to affect urban, suburban and rural 
populations in the province and remain above historical averages despite targeted services, with 
981illegal drug toxicity-related deaths in 2019, and the detection of fentanyl in 85% of those 
cases (Coroners Service, 2020). The exact prevalence of OUD within the province has not yet 
been established, but it is estimated to impact approximately 2.1% of the American population 
(BCCSU & BCMOH, 2017). 
The ongoing opioid crisis has held the public’s attention and has further exposed the 
unique stigma associated with OUD. Through data collection completed by Statistics Canada in 
2017, the highest level of awareness regarding the opioid crisis in Canada was found to be in the 
province of British Columbia, with 86% of respondents reporting they were ‘very aware’ of the 
issue (2018). Those who reported they were ‘very aware’ were more likely to agree that if they 
had an opioid dependency they would feel comfortable seeking help or treatment, versus those 
who were unaware of the opioid crisis (83% versus 70%) (Statistics Canada, 2018). In this same 
survey, 36% of Canadians aged 18 years and older responded that they would not want family or 
friends to know if they were using opioids without a prescription (Statistics Canada, 2018).  
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Diagnosis of Opioid Use Disorder 
Opioid use disorder (OUD) has been identified as one of the most challenging forms of 
substance use disorders facing health care systems and is a major driver of the recent surge in 
illegal drug overdoses (BCCSU & BCMOH, 2017). It is chronic, relapsing, and is associated 
with significant increased rates of morbidity and mortality (Bruneau et al., 2018) This clinical 
disorder is characterized by at least two of the symptoms listed in the Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition (DSM-5) for diagnosis, which can be established by 
primary care providers in British Columbia (see Appendix A for DSM-5 criteria). OUD can be 
categorized as mild, moderate, or severe, and may involve non-medical pharmaceutical opioid 
use or the use of illegally manufactured opioids such as heroin or fentanyl (American Psychiatric 
Association, 2013; Kennedy-Hendricks et al., 2016). 
The latest DSM edition has progressed from its predecessor by making efforts towards 
destigmatizing the medical diagnostic language used. This de-stigmatization involved removing 
the terms ‘opioid dependency’ and ‘opioid abuse’ from the criteria (Broyles et al., 2014). This 
revision was imperative considering that the use of such terms is pejorative, implicitly generates 
bias, perpetuates stigmatizing attitudes, and influences social and public health policy when 
addressing OUD as a health concern (Kelly et al., 2016). Further, describing an individual as an 
‘opioid abuser’ conveys willful misconduct and suggests that the person ‘is’ the problem, 
whereas ‘OUD’ conveys that a person ‘has’ a medical problem, rather than ‘is’ the problem 
(Kelly et al., 2016). ‘Opioid addict’ and ‘opioid addiction’ are also not included within the new 
terminology as these terms imply opioid use is a willful choice and that those who are ‘addicted’ 
really can control their opioid use (Kelly et al., 2016; Collins et al., 2018). Describing an 
individual’s unregulated drug use as ‘illicit’ should also be avoided, as it conveys the individual 
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as unlawful and unacceptable, influencing judgements pertaining to the need for punishment 
versus treatment (Kelly et al., 2016). Further, the use of stigmatizing language is morally 
centered and amongst health care providers this can have impacts on attitudes and create barriers 
to accessing care (Collins et al., 2018). This differentiation in the terms is important to employ 
‘people first language’ which seeks to respect the person’s individuality by acknowledging that 
their illness is not their defining characteristic while maintaining attention on the medical aspects 
of their disease (Broyles et al., 2014).  
Risk Factors and Comorbidities of Opioid Use Disorder  
 
 Opioid use occurs on a wide spectrum and understanding why a person may be 
vulnerable to developing OUD is complex. There are no exact estimates of the epidemiology of 
OUD in British Columbia, but there are identifiable risk factors that may contribute to this illness 
which can help guide screening, monitoring and implementation of early intervention. It is 
estimated individuals between ages 18 and 29 years old have the highest prevalence of 
developing an OUD, which usually endures for long periods of time with episodes of abstinence 
and relapse (McCarberg, 2015). Individuals may use opioids for a multitude of reasons including 
to experiment out of curiosity, impacts of adverse childhood experiences, to self-medicate for 
physical, mental or emotional pain related to trauma, to cope with anxiety, to reward oneself, or 
to stimulate creative endeavours (Office of the Provincial Health Officer, 2019; Stein et al., 
2017). Factors related to individual, family, peer, social and environmental domains as well as a 
genetic component may predispose a person to increased opioid use (McCarberg, 2015). Similar 
to other substances, several extrinsic risk factors increase an individual’s likelihood to use 
opioids including ease of access to opioids, academic failure, physical or sexual abuse, earlier 
age at first use and socioeconomical disadvantage (Mistry et al., 2014). With regards to 
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developing a prescription OUD, evidence suggests there is a substantial increase in the likelihood 
for those individuals with a history of opioid or nonopioid substance use disorder, and/or a 
mental health diagnosis (Klimas et al., 2019). Further, certain characteristics of opioid 
prescriptions may influence development of a prescription OUD such as supplying more than 30 
days’ worth of medication, daily doses exceeding 120 morphine milligram equivalents, and 
concurrent prescription of atypical antipsychotics (Klimas et al., 2019). Individuals who use 
prescription opioids beyond medical purposes are more susceptible to using illegal opioids, and 
an increased rate of unregulated heroin use in recent years has been attributed to the overuse of 
prescription opioids (Kennedy-Hendricks et al., 2016).  
Provincial data regarding the opioid overdose crisis may help indicate sub populations at 
increased risk for developing OUD. An overrepresentation of First Nations people, including 
both males and females, is present in the unregulated drug supply overdose death toll, with First 
Nations people three times more likely to suffer a fatal drug overdose than non-First Nations 
(Office of the Provincial Health Officer, 2019; First Nations Health Authority, n.d.). Another 
subpopulation at increased risk are males age 19 to 59, as this group represents the largest 
proportion of the province’s accidental illegal drug fatal overdoses (BCCDC, 2020).  
Evidence Based Treatment and Primary Care Context in British Columbia 
 
In order to optimally treat OUD in British Columbia, there needs to be increased access 
to comprehensive care and appropriate evidenced-based therapy options, such as opioid agonists 
(BCCSU & BCMOH, 2017). Opioid agonist therapy (OAT), which can also be referred to as 
opioid substitution treatment, alleviates withdrawal symptoms, encourages sustained abstinence 
from opioid use, reduces risk behaviours associated with injection drug use, and reduces risk of 
morbidity and mortality (BCCSU & BCMOH, 2017; Noysk et al., 2013). These medications 
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induce less euphoria than opioids and oral formulations can be safely prescribed in primary care 
settings (Livingston et al., 2018). The available options in British Columbia are 
buprenorphine/naloxone, methadone, and slow release oral morphine (BCCSU & BCMOH, 
2017). Ideally, patients receive an induction dose with careful monitoring of treatment response 
and are subsequently stabilized on a therapeutic dose with the goal of controlled withdrawal 
symptoms and reduced or eliminated opioid cravings (BCCSU & BCMOH, 2017). Fortunately, 
there is an increasing trend in the number of OAT prescribers in British Columbia since mid-
2016, with a total of n=1487 in January of 2020 (BCCDC, 2020). Despite these numbers, 
evidence suggests that fewer than 25% of Canadians with OUD are receiving this evidence-
based pharmacotherapy treatment, indicating that either more OAT prescribers are needed, or a 
gap remains between current practice and evidence-based standards (Stuart, 2019).  
Primary care providers within British Columbia are well supported to provide safe and 
comprehensive care for the population struggling with OUD. There are a number of accessible 
resources, including recent provincial guidelines for the Clinical Management of OUD from the 
British Columbia Center on Substance Use (BCCSU) and the Ministry of Health, as well as an 
online training course called the Provincial Opioid Addiction Treatment Support Program 
(University of British Columbia [UBC], n.d.). These evidence-based guidelines and educational 
module are pertinent to all health care professionals but are especially relevant to primary care 
providers to engage with to establish OUD diagnosis, create a patient centered care plan, safely 
prescribe OAT, integrate harm reduction and practice trauma informed care (UBC, n.d.). The 
BCCSU supports all primary care providers in British Columbia to become competent oral OAT 
prescribers through completion of paid training and a preceptorship in a supervised clinical 
setting with an approved OAT prescriber (BCCSU, 2020a). Once these requirements are met, a 
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primary care provider is able to initiate and continue prescriptions for oral OAT with further 
province-wide guidance readily available from a substance use specialist through the Rapid 
Access to Consultative Expertise (Rapid Access to Consultative Expertise, n.d.). 
Cause, Controllability and Criminalization 
 
Research indicates that negative attitudes towards individuals who struggle with a 
substance use disorder are significantly increased compared to attitudes about mental illness 
(Barry et al., 2014; Goodyear et al., 2018). This heightened stigma seems to be influenced by 
two main factors: cause and controllability (Kelly et al., 2016). For example, the perception 
exists that those with OUD have increased control over their illness, and are therefore more 
accountable for their behaviour, or that drug users have moral shortcomings; the illegality of 
using unregulated opioids supports this perspective (Barry et al., 2014; Goodyear et al., 2018). 
Further, a misconception held by the public and health professionals that OUD is a willful choice 
and not a disease is also a mediator of this stigma, causing it to be separated from the rest of the 
medical system (Wakeman & Rich, 2018; Kelly et al., 2016). In cases where the criminal justice 
approach has been applied, individuals may be channelled into a jail sentence for possession of a 
small amount of an illegal substance while disregarding what is ultimately a health issue (Kelly 
et al., 2016). The engagement of an individual with the criminal justice system also exposes a 
person to a great deal of harm that they may not have otherwise been subjected to (Office of the 
Provincial Health Officer, 2019). Societal stigma and criminalization of this vulnerable 
population encourages drug use in private or hidden drug use, thereby increasing the risk of 
overdose (Office of the Provincial Health Officer, 2019). It has been recognized worldwide that 
the ‘war on drugs’ has failed, resulting in an increase in health harms and no reduction in drug 
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use, yet decriminalization in British Columbia has not been achieved despite the prevalence of a 
toxic, unregulated, illegal street supply (Office of the Provincial Health Officer, 2019). 
This section of this paper has provided pertinent background to ensure the variables, 
populations and issues of interest are clarified. By providing this context to clearly identify the 
problem, accuracy and focus will be maintained in the next portion of the integrative review 
process (Whittemore & Knafl, 2005). 
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Chapter III: Methods 
Integrative Literature Review 
 
 An integrative literature review is the broadest approach to a research review, allowing 
for inclusion of both experimental and non-experimental study designs to encourage a complete 
appreciation of the clinical phenomenon of concern (Whittemore & Knafl, 2005). The 
framework to guide this integrative literature review will encompass the methodology of 
Whittemore & Knafl which includes five stages: problem identification, literature search, data 
evaluation, data analysis, and presentation (2005). This approach to the review will allow for the 
inclusion of a combination of research methodologies allowing readers a more comprehensive 
understanding of the complexity of the clinical concern (Whittemore & Knafl, 2005).This 
chapter of the paper will outline the literature search, the inclusion and exclusion criteria for the 
chosen articles, the data evaluation and the data analysis. 
Literature Search 
 
A well-defined search strategy is a critical component for an integrative review to ensure 
thorough and unbiased results (Whittemore & Knafl, 2005). As the focus of the review is related 
to the ongoing North American opioid crisis, this has sparked the necessity of further research 
and monitoring to be completed as of recent. The topic’s relevance further substantiates the 
purpose of undertaking a review of this pertinent literature, as updates to evidence are ongoing to 
support best practices when providing care for this vulnerable population; however, the latest 
research evidence may be inconsistent with current clinical practice. The literature search was 
conducted to identify sources that helped to inform understanding the impacts of stigma for 
adults with OUD in primary care settings of British Columbia. The following section will discuss 
the search methods utilized for obtaining applicable literature to inform the review. 
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Search Strategy 
First, a comprehensive search for applicable literature was completed through the 
University of Northern British Columbia Library computerized database system to efficiently 
maximize eligible peer reviewed sources. Three themes related to the clinical phenomenon of 
concern were used to guide the terminology for each search: Stigma, OUD, and the primary care 
setting. After reviewing the initial database results, the reference lists of pertinent articles were 
reviewed to maximize the number of eligible sources as well as identify related grey literature. 
During this search process the inclusion and exclusion criteria were considered to ensure 
elimination of duplicate or irrelevant articles. The following section describes the literature 
search process in detail. 
Preliminary Search 
The initial search was completed utilizing the library’s databases to maximize the scope 
of the literature. The five electronic bibliographic databases utilized for the electronic searches 
were: Cumulative Index of Nursing and Allied Health Literature (CINAHL), MEDLINE, 
PyscARTICLES, PsycINFO and PubMed. These databases were chosen for their relevance to 
mental health, behavioural science and health care. A combination of MeSH and non-MeSH 
keywords or only non-MeSH keywords were used, depending on the database system after a trial 
and error process. Stigmatizing keywords were included in searches, for example ‘addict’ and 
‘opioid abuse’ for the reason that these may have been more commonly utilized in previous 
publications. These types of terms will likely be phased out in peer reviewed literature moving 
forward due to their harmful impact on the vulnerable population they are attempting to describe; 
but excluding them may cause an elimination of some of the best relevant literature. 
Furthermore, including these kinds of terms upholds with the guideline of the simultaneously 
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including multiple types of research when conducting an integrative review to more fully 
understand the phenomenon of interest; especially a clinical concern as complex as stigma’s 
impact on those struggling with OUD (Whittemore & Knafl, 2005). The addition of a 
geographical context was considered to be included as a keyword to guide the search; however, 
the inclusion of British Columbia as a subject heading or keyword with the Boolean phrase AND 
resulted in zero sources and was therefore removed to expand the search results. Each database 
was individually searched and the detail of each search including the subject headings (MeSH) 
and keywords (non-MeSH) used can be found in Appendix B. 
The combination of these keywords resulted in varying numbers of results for each 
database, ranging from n=3 to n=132 results for a combined database total of n=276. After 
duplicates were removed, a total of n=196 results remained. These records were then screened to 
ensure they were published during or after the year 2010, peer reviewed, and written in English. 
This screening was done to ensure the most rigorous, up to date data and to remove potential 
language barriers; the result was n=167 citations. The titles and abstracts were then reviewed to 
ensure relevancy to the concept of interest. Articles that addressed the impacts of stigma 
associated with the care of individuals with OUD in primary care settings within a North 
American context were selected for full text review and this number was n=23.  
Secondary Search 
 Hand searching reference lists was also done to ensure that all relevant sources of 
research were included. Articles found through this method (n=11) addressed variable relations 
of stigma and opioid use in a healthcare context or provided a probable background detailing 
how stigma relates to primary health care delivery to individuals with OUD. Purposive sampling 
by reviewing the online database of primary source publications from authors belonging to the 
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British Columbia Centre for Substance Use (BCCSU) was done as an additional strategy in an 
attempt to seek out sources providing local context and to identify the maximum number of 
eligible and relevant sources. This step was pertinent as the mission of this provincial network of 
researchers is to provide leadership in substance use and substance use disorder research and 
share the knowledge widely (BCCSU, 2020b). Unfortunately, no articles specific to stigma and 
how it relates to OUD were available in within the list of journal articles. A Prisma flow diagram 
is attached in Appendix C for a clear depiction of how the final articles were confirmed. 
Exclusion and Inclusion Criteria 
Peer reviewed sources published between 2010-2020 were reviewed for relevancy as the 
clinical context and management of OUD in primary care has evolved within this timeframe. 
Each article’s title and abstract were hand reviewed and studies completed in North America and 
Western Europe were considered for their social and cultural similarities to the British Columbia 
setting. Study populations including members of the public, primary care providers, or adults 
(>18 years old) with OUD were chosen for review as these participants’ perspectives informed 
the clinical question’s populations of interest and addressed the primary care context. Please see 
Table 1 below for all inclusion and exclusion criteria listed. 
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Table 1 
Inclusion and Exclusion Criteria for Selection of Articles 
Inclusion Criteria Exclusion Criteria 
-Published 2010-2020 
-Published in North America or Western 
Europe 
-Studies relevant to stigma associated with 
opioid use disorder that are applicable to the 
primary care setting 
-Adult population (>18 years old) 
-English language 
-Peer reviewed 
-Publication date older than 2010 
-Studies from South America, Asia and 
Eastern Europe  
-Studies specific to health care professionals 
that are not primary care providers: 
Emergency physicians, hospitalist physicians, 
counsellors, social workers 
-Comorbid mental health diagnosis 
-Specific study populations: incarcerated 
individuals, veterans, pregnant women, 
postpartum mothers, sex workers, HIV 
infection, Hepatitis C infection, sickle cell 
disease, individuals with chronic pain 
-Studies specific to American health care 
system- drug monitoring programs, hub and 
spoke programs, Medicaid coverage 
-Unpublished manuscripts: dissertations, 
abstracts 
-Expert opinion style reviews 
 
To keep the review focused, further specific exclusion criteria were applied to filter 
results. Studies pertaining to comorbid mental health disorders and other specified substance use 
disorders, such as alcohol use disorder, were excluded since the purpose of this review is to 
address stigma unique to OUD and acknowledgement of the complexities of coexisting 
comorbidities is well beyond the scope of this paper. Similarly, specific subset populations with 
OUD, such as patients with comorbid blood borne infections, chronic pain, pregnant women, 
veterans, incarcerated individuals and those involved in sex-related work were chosen to be 
excluded because the intent of the review is to be generalizable to all adults experiencing OUD. 
Articles that addressed stigma amongst specific health care professionals such as social workers, 
counsellors and emergency room physicians were also excluded to maintain the aim of informing 
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primary care providers. Many publications from the United States of America (USA) 
consistently referred to specific state health care systems in place to manage OUD such as the 
‘hub and spoke program’, which is similar to one large urban hospital in British Columbia that 
has a hub within its emergency department to support patients with non-specific mental health or 
substance use challenges (Providence Health Care, n.d.). As this model is non-specific to OUD 
and not applicable to the context of health care systems in place across the province, these papers 
were also removed from the analysis.  
A total of eleven sources were appraised as eligible to undergo analysis for this 
integrative literature review, consisting of eight primary research studies, two literature reviews 
and one policy forum. Prisma flow diagram is attached in Appendix C. 
Data Evaluation 
 
As the chosen research to inform this literature review are from a diverse sampling frame, 
the extraction of specific methodological features is not warranted to evaluate the overall quality 
of the chosen literature (Whittemore & Knafl, 2005). For this reason, the authenticity, 
methodological quality, informational value and the representativeness of the included primary 
sources will be discussed along with the calculated quality scores to optimize the analysis 
(Whittemore & Knafl, 2005). The variable criteria to exemplify quality of the other research 
designs will also be applied and presented as a rating within the attached literature matrix 
(Whittemore & Knafl, 2005). As there is no gold standard for interpretation of quality in research 
reviews, a combination of recognized analysis tools was used to evaluate the trustworthiness, 
relevance and results of the literature sample (Whittemore & Knafl, 2005). Each article was 
assessed using either the applicable Critical Appraisal Skills Programme (CASP) checklist tool, 
the appropriate Joanna Briggs Institute (JBI) Critical Appraisal Checklist, or, for citations whose 
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methodology did not meet any of the CASP or JBI tools, the John Hopkins Nursing Evidence-
Based Practice Research Evidence Appraisal Tool.  
Data Analysis 
The data analysis of an integrative literature review aims to provide a thorough and 
unbiased explanation of the research sample through a process of organizing the data in an 
integrated fashion to form conclusions about the focus of the review (Whittemore & Knafl, 
2005). To facilitate thorough analysis, the chosen sources have been divided and organized into 
subgroups based on study type: primary sources; qualitative, quantitative and mixed method 
designs, secondary sources; two literature reviews and one policy forum paper. To facilitate data 
reduction and data display, a literature matrix was utilized to simplify, abstract, focus and 
organize the findings (see Appendix D). This data display helps to discern the pattern distinction 
while facilitating a systematic comparison of the sources for certain variables or characteristics 
(Whittemore & Knafl, 2005). The critical analysis and quality rating of each citation is also 
presented here. As the chosen literature is of diverse methodologies, the data extraction involved 
a distinction of themes, variations and relationships with similar data grouped together for 
comparison (Whittemore & Knafl, 2005). The next step in the process of the analysis is data 
comparison and is presented in the findings section, found in the following chapter of this paper, 
where an iterative process will thoroughly examine the patterns identified in the data 
(Whittemore & Knafl, 2005).  
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Chapter IV: Findings 
Critical Review of the Literature 
 
An array of primary research methodologies with varying participant populations were 
selected to inform this integrative literature review, allowing for a diverse inquiry into the 
complex phenomenon of stigma as it relates to OUD. The primary studies included research 
conducted to understand the attitudes of patients (n=2) (Antoniou et al., 2019; Kulesza et al., 
2017), physicians in primary care (n=3) (Livingston et al., 2018; Kennedy-Hendricks et al.; 
2016; Deflavio et al., 2015), members of the public (n=2) (Goodyear et al., 2018; Kennedy-
Hendricks et al., 2017) and members of a health care team including primary care providers 
(n=1) (Khenti et al., 2019). These studies encompassed quantitative (n=4) (Goodyear et al., 
2018; Kennedy-Hendricks et al., 2016; Kennedy-Hendricks et al., 2017; Kulesza et al., 2017), 
qualitative (n=2) (Antoniou et al., 2019; Livingston et al., 2018) as well as mixed methods 
designs (n=2) (Deflavio et al., 2015; Khenti et al., 2017). Of these, five (62%) (Deflavio et al., 
2015; Goodyear et al., 2018; Kennedy-Hendricks et al., 2016; Kennedy-Hendricks et al., 2017; 
Kulesza et al., 2017) were conducted in the USA and three (38%) (Antoniou et al., 2019; Khenti 
et al., 2017; Livingston et al., 2018) were from Canada. Of the secondary sources, the narrative 
review comprised only studies published in the USA (Louie et al., 2019), the systematic review 
encompassed studies from only western countries (van Boekel et al., 2013), and the policy forum 
paper addressed circumstances specific to the USA (Tsai et al., 2019). 
Overall, the CASP appraisal ratings of the qualitative primary research and systematic 
review were of high quality (n=3) (Antoniou et al., 2019; Livingston et al., 2018; van Boekel et 
al., 2013). A high JBI rating was applied to one quantitative primary research study and the 
policy forum paper (n=2) (Kennedy-Hendricks et al., 2017; Tsai et al., 2019) with the remaining 
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quantitative primary study appraised as ‘good’ quality (n=1) (Kulesza et al., 2017). The John 
Hopkins critical appraisals applied to the remaining mixed methods designs and one narrative 
review revealed two high quality (n=2) (Deflavio et al., 2015; Goodyear et al., 2018) and three 
good quality (n=3) (Kennedy-Hendricks et al., 2016; Khenti et al., 2017; Louie et al., 2019). 
Each of these papers are outlined in the literature matrix in Appendix D with information 
regarding the methodology, sampling, strengths, limitations and the key findings. The critical 
appraisal quality of each are also encompassed in the matrix.  
In this section, the findings of the integrated literature review will be presented by 
comparing the data and identifying accurate and meaningful themes abstracted from the chosen 
literature. This iterative process will also recognize relationships between variables within the 
literature sample (Whittemore & Knafl, 2005). Through critical analysis of the findings from 
each study, common patterns emerged and will be presented here in the way they relate to the 
barriers that stigma maintains for patients with OUD in British Columbia. A presentation of 
these findings will seek to depict the varying levels of stigma related to OUD and identify focal 
points to inform primary care providers on ways to ameliorate their practices to eliminate stigma 
in British Columbia. The themes are classified as (a) professional stigma characterized by 
discrimination of patients, mistrust of patients, stigma related to OAT, and insufficient 
education; (b) patient stigma expressed as internalized and perceived stigma; (c) stigmatizing 
language; (d) public stigma; (e) opioid familiarity; (f) stigma and opioid policy. The 
interpretative efforts of each theme are presented in the following section.  
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Professional Stigma 
Discrimination of Patients 
All five studies examining the attitudes of health care professionals conveyed varying 
forms of discrimination toward patients related to their opioid use or diagnosis of OUD which 
created apprehension to provide their care or interact with them in social contexts. A survey of a 
large sample of primary care physicians revealed a high level of desire for social distance from 
those with a prescription OUD with a large majority of respondents unwilling to have a person 
with prescription OUD marry into the family (79%) or work closely with them on the job (77%) 
(Kennedy-Hendricks et al., 2016). Louie et al. (2019) included this data within their narrative 
review to strengthen their findings to describe the culture of prevalent stigma within the inner 
settings of health care related to OUD. This in accordance with van Boekel et al. (2013) 
identification of two studies in their systematic review that health professionals regard for caring 
for people who use drugs is consistently lower when compared to other patient groups, such as 
patients with depression, and strong negative attitudes exist towards illegal drug users, with most 
professionals preferring that substance use specialists exclusively provide care for illegal drug 
users. 
One primary care provider respondent provided an example of the stereotypical nature of 
how these patients are perceived in primary care settings: “there’s a great deal of fear in primary 
care… around people with addiction… especially opiates” (Livingston et al., 2018, p. 348). This 
apprehension was verified by Kennedy-Hendricks et al. (2016) as more than half (66%) of 
primary care physician participants viewed individuals with prescription OUD as more 
dangerous than the general population. In their policy forum paper, Tsai et al. (2019) recognized 
the dangerous stereotype of patients who use opioids may reflect why many buprenorphine 
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waivered physicians in the USA are not prescribing at capacity or express little interest to do so. 
This was validated further in the Canadian study by Livingston et al. (2018) where fears for 
safety were explicitly expressed from primary care providers when asked about considering 
introducing methadone treatment into their practice. One of the non-methadone prescribers from 
a rural area in this study described distress related to living in a small community as “these 
patients know where we live” (Livingston et al., 2018, p. 350), which certainly applies to the 
context of providing primary health care in rural and remote British Columbia. Participants had 
strong unease due to the possibility of intimidating or aggressive behaviour, verbal threats, or 
physical violence that would be disruptive to their family practice environment and “might scare 
away normal patients” (Livingston et al., 2018, p. 349). A current methadone prescriber within 
this study endorsed feeling the presence of an undertone of the potential for violent behaviour 
among her patients on methadone that was not present with her other patient populations 
(Livingston et al., 2018). Within their systematic review, van Boekel et al. (2013) also found 
results confirming that general practitioners perceive people who use drugs as aggressive.  
In Deflavio et al. (2015) survey, 94% of family physicians reported treating patients with 
OUD as difficult, referring to them as high maintenance, stressful, and challenging. Difficulty 
and challenging were also descriptors in the results from Louie et al. (2019) and Livingston et al. 
(2018), with one respondent describing that many patients with OUD “…are not very good 
people” (Livingston et al., 2018, p. 348). These primary care provider participants also referred 
to perceptions of associated disarray for patients with OUD and related this to the concurrent 
poverty, unemployment, crime, poor access to transportation, housing instability, traumatic 
experiences, poor relationships and comorbidities frequently associated with this patient 
population (Livingston et al., 2018). These adverse life circumstances were viewed as complex 
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needs that are problematic to manage within the primary care setting, which is disconcerting 
given that a main goal of primary health care services is to encompass the social determinants of 
health (Livingston et al., 2018). Similar observations were found in Louie et al. (2019) narrative 
review, with other physician respondents bluntly reporting “we don’t want these type of patients 
in our clinics” (Louie et al., 2019, p. 3), and describing providing care related to OUD as “not 
what we do here in here in primary care” (Louie et al., 2019, p. 3).  
Mistrust of Patients 
A common theme found within the integrative literature review was the propensity of 
health professionals that commonly held a lack of trust toward patients with OUD, thereby 
creating reluctance to provide care for this population. This was evident in Deflavio et al. (2015) 
study, which collected anonymous quantitative and qualitative survey data, where written 
responses conveyed high levels of mistrust. One family physician reported they would rather not 
“deal with addicts who lie” (Deflavio et al., 2015, p. 6) while another noted that they were “not 
set up… as a police agency” (Deflavio et al., 2015, p. 6). Livingston et al. (2018) also found that 
primary care provider participants frequently perceived patients as deceptive as well as 
manipulative and described being “sucked in” (Livingston et al., 2018, p. 348), leading to 
feelings of frustration. This is in accordance with van Boekel, Brouwers, van Weeghel and 
Garretsen’s systematic review (2013) results that manipulative behaviour is often perceived by 
general practitioners when encountering patients with a substance use disorder, resulting in 
feelings of resentment, powerlessness and dissatisfaction. Louie et al. (2019) narrative review 
findings further conveyed a sense of mistrust, recognizing widespread suspicion of opioid users 
amongst primary care providers, both personally and professionally. In describing their 
hesitations towards treating OUD and preferring that a substance use specialist manage this 
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condition, one primary care provider explained that “this population tends to be squirrelly, they 
don’t tend to be honest with you…” (Louie et al., 2019, p. 5). 
Diminished trust was also identified with respect to the nature of patient-provider 
interactions when providing care for patients who use opioids. For example, surveillance 
activities associated with some treatment programs for patients receiving methadone 
maintenance therapy left primary care providers feeling like they were interacting with patients 
in a way that was distrusting and promoted a paternalistic relationship; for instance, having to 
watch patients urinate to ensure a valid sample was obtained (Livingston et al., 2018). The study 
respondents described this type of mandatory practice standard to “do what you should be doing 
as a good doctor” (Livingston et al., 2018, p. 349), but made patient interactions feel like an 
interrogation while simultaneously attempting to establish a therapeutic and non-judgemental 
rapport. Similar evidence was also recognized by Tsai et al. (2019) as they identify the 
supervision, monitoring and restrictive dispensing policies of methadone delivery can subject 
individuals to degrading and humiliating experiences. 
Mistrust was also palpable in the studies exploring patient perspectives. Antoniou et al. 
(2019) verified that since opioid deprescribing and opioid policy changes were implemented in 
Canada in 2017, patients who regularly use opioids perceive manifestations of mistrust and 
suspicion, as well as experiences of disrespect and paternalism during interactions with their care 
providers. Regarding patients’ perceptions of their own trustworthiness, Kulesza et al. (2017) 
found that among its primary care patient participants with OUD, they were least likely to report 
feelings that they cannot be trusted (4%), based on a reliable tool evaluating eight internalized 
stigma items.  
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Stigma Related to Opioid Agonist Treatment 
Stigma remains a significant barrier towards the adoption and implementation of opioid 
agonist treatment (OAT) into routine practice, a finding that was widely reported amongst the 
studies that reviewed attitudes of prescribers as well as potential prescribers. A mistrust of the 
efficacy of buprenorphine was reported by both Louie et al. (2019) and Deflavio et al. (2015). In 
their narrative review, Louie et al. (2019) found negative attitudes and skepticism were 
frequently reported against buprenorphine as a legitimate treatment option amongst primary care 
providers. Additionally, both of these sources confirmed providers who were non-prescribers 
were more likely to estimate lower efficacy of buprenorphine than those who did prescribe 
(Louie et al., 2019; Deflavio et al., 2015). There were no reported uncertainties regarding the 
efficacy of methadone in Livingston et al. (2018) inquiry of primary care providers; however, a 
lack of confidence existed in the basis of providing long term OAT. One physician questioned 
indefinite methadone use as “just substituting one drug for another forever then I wonder what’s 
the point?” (Livingston et al., 2018, p.348), and this was similar to expressed concern from non-
prescribers in Deflavio et al. (2015) qualitative data collection. The results from Kennedy-
Hendricks et al. (2016) data indicated the majority of primary care provider respondents were 
supportive of treatment for OUD, with 58% believing effective treatment options are available to 
help people with OUD, and 69% trusting that most patients with a prescription OUD can get well 
with treatment. Although these results indicate a majority, it is notable that many respondents did 
not believe effective treatment is available, despite existing current evidence indicating the 
clinical effectiveness of OAT.  
There was general concern amongst providers that becoming an OAT prescriber would 
result in attracting an unwanted patient population which overlapped with concerns that the 
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stigma of OUD would rub off on the clinic (Louie et al., 2019; Livingston et al., 2018). Further, 
anxiety was present amongst providers that OAT prescribing could be a potential threat to their 
career and professional reputation, as cited in Louie et al. (2019), Livingston et al. (2019), and 
Deflavio et al. (2015). These concerns were linked to the potential for buprenorphine to be 
diverted as identified by Deflavio et al. (2015) and Louie et al. (2019). On becoming a 
methadone prescriber, one respondent reported angst that his licence would become 
compromised by “addicts” (Livingston et al., 2018, p. 349) due to elevated scrutiny of regulatory 
bodies and inequality in methadone’s regulation. This specific finding should be interpreted 
bearing in mind that data collection occurred prior to the removal of the previous requirement of 
having to obtain an exemption to prescribe methadone in Canada under federal policy, which has 
since been removed in mid 2018 (CPSBC, 2020). Louie et al. (2019) also expressed the rural 
sample populations included in their analysis conveyed similar apprehensions in prescribing 
OAT when compared to the urban physicians in their analysis of the literature sample, of which 
some results may be pertinent to British Columbia’s rural primary care providers, with 
consideration all data originated in the USA.  
Insufficient Education 
Consistent reports of lack of knowledge and training specific to OUD existed among 
participants. van Boekel et al., (2013) concluded that generally health professionals tend to have 
low levels of knowledge about substance use disorders and feel they lack specific understanding 
and skills to care for this particular patient group. This finding was confirmed by a large majority 
of family physician respondents reporting inadequate staff training as the number one reason for 
not providing treatment for OUD patients in their practice (88%) (Deflavio et al., 2015). 
Livingston et al. (2018) identified a minority of participants had learned or acquired skills to 
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manage substance use disorders in medical school with one physician stating “we didn’t get a lot 
of training in that area of medicine… it’s more like a fringe topic” (Livingston et al., 2018, p. 
350), fostering the notion that OUD is outside the realm of legitimate medical conditions. 
Amongst primary care provider respondents in Kennedy-Hendricks et al. (2016) the majority 
(72%) felt prescription OUD is a very serious problem; however, they ranked its seriousness 
below other major chronic illness: obesity, heart disease, and tobacco use, which may 
additionally indicate an unclear understanding of OUD as a complex, chronic medical condition 
may exist amongst primary care providers.  
Khenti et al. (2019) mixed methods evaluation was the only longitudinal study included 
in the review that implemented an intervention to assess for a reduction in stigma toward patients 
with OUD. This original research was conducted within community health centre settings that 
utilized the primary health care model in Ontario, and the intervention included improving 
awareness and providing education to health care providers (Khenti et al., 2019). The authors’ 
results confirmed a significant reduction in stigmatizing attitudes post intervention, including 
strong evidence in particular for the measure specifically linked to OUD (p < 0.05) (Khenti et al., 
2019). This study is generalizable to the context of primary health care in British Columbia and 
verifies that persistent professional stigma related to OUD may be associated with insufficient 
attention to substance use disorders in education and training, in keeping with the conclusions 
drawn from van Boekel et al. (2013), Deflavio et al. (2015), Livingston et al. (2018), and 
Kennedy-Hendricks et al. (2016). These findings also closely relate to the stigma towards the 
efficacy and implementation of OAT, as many providers seem to lack knowledge or fail to 
recognize the clinical effectiveness of this evidenced-based therapy. 
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Patient Stigma 
Internalized and Perceived Stigma 
Self-stigma was reported in both of the primary studies of the review with patient 
participants as well as in the systematic review. In their primary study to examine a population of 
primary care patients with opioid or alcohol use disorders in the USA, Kulesza et al. (2017) 
found internalized stigma was common amongst the participants and was the strongest predictor 
of substance use related problems. Although the tool employed contained stigmatizing terms that 
had the potential to generate participant bias, respondents were most likely to report feeling 
ashamed or that they have permanently screwed up their lives as a result of their OUD (Kulesza 
et al., 2017). Significantly higher internalized stigma was present amongst participants with 
OUD and comorbid alcohol use disorder (Kulesza et al., 2017). Tsai et al. (2019) also recognized 
internalized stigma is commonly experienced by individuals with OUD in their policy forum 
paper to acknowledge its significant association with psychological distress, poorer quality of 
life, continued substance use, and reduced engagement with treatment.  
Perceived stigma was also evident amongst patients with OUD as described by the 
primary qualitative study investigating adults who use opioids in Ontario, with participants 
expressing concern that a diagnosis of OUD would disqualify them from future health care, 
particularly involving appropriate pain management (for example, if they required surgery) 
(Antoniou et al., 2019). These participants related health seeking experiences to be occurring in a 
context where their opioid use was a permanent, discreditable attribute that had become central 
to their identities, causing some to forego help seeking entirely (Antoniou et al., 2019). One 
participant described feeling: 
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Quite ill… but I didn’t go because of the stigma… and I thought …as soon as I go on 
methadone I am not going to get the medical help I need… because they are going to 
judge me and I experienced that… I didn’t get that medical attention because I was an 
addict and judged (Antoniou et al., 2019, p. 18) 
Another participant in this study addressed the challenges having physicians relate and 
empathize with their life circumstances alluding to the affirmation of peer integration within the 
provision of care by describing: 
The problem is that… people that are trying to help us can’t relate to [our] story where I 
can relate to their story of eating out of garbage cans, I can relate to being a prostitute… 
because I did all these things right? But when you… try to put all that out there, their 
blinders automatically go up and they stop taking you seriously… Hire some people that 
are still using (Antoniou et al., 2019, p. 19) 
van Boekel et al. (2013) systematic review further acknowledged the consequences of 
negative attitudes on healthcare delivery. Two studies confirmed patient participants who 
reported greater perceived discrimination from health care professionals were less likely to 
complete treatment and predicted dropout rates (van Boekel et al., 2013). The population 
characteristics of these studies were not made available within the review and the authors 
informed readers that few studies were available to inform the impacts of perceived professional 
discrimination. For these reasons, these results may indicate that negative attitudes can be 
perceived by patients with negative outcomes, but there is limited external validity applicable to 
the primary health care context of British Columbia. A discussion of the anticipated stigma 
suffered by patients with OUD was also acknowledged by Tsai et al. (2019) and associated with 
psychological distress and reduced engagement in care. The authors also recognized these 
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impacts can be pronounced in rural areas and small communities due to heightened concerns 
about boundary violations or breaches of confidentially (Tsai et al., 2019). This is relevant given 
the geographical context of rural and remote primary care settings in the province and the extent 
of the opioid overdose crisis across all areas of British Columbia. 
Stigmatizing Language 
Stigmatizing language was displayed within qualitative data from the studies 
investigating health care professionals and I have provided quotes throughout the findings to 
help portray this. Tsai et al. (2019) identify that everyday language used surrounding the current 
opioid crisis and individuals with OUD attributes to considerable consequences related to 
responsibility, increased support for punitive judgements and devalued evidence-based 
treatments. This includes terms such as substance abuser, and medication assisted treatment (Tsai 
et al.; 2019). The authors also suggest referring to the current opioid crisis as an ‘epidemic’ 
invokes isolation, quarantine and vector control, which are inappropriate in response to the 
multifactorial opioid overdose crisis (Tsai et al., 2019). They recognize that language has the 
power to shift public stigma, a conclusion which was also supported in the study by Goodyear et 
al. (2018) that completed a vignette survey amongst a large random sample of the public in the 
USA. Their findings concluded that individuals labelled as ‘drug addicts’ held a higher 
responsibility and negative affect ratings compared to those labelled with ‘OUD’ (Goodyear et 
al., 2018). Further, the authors identified that language may matter for males and females, as the 
OUD label was rated with higher dangerousness than ‘drug addict’ in females; ‘drug addict’ was  
rated with higher negative affect ratings than disorder, and males had lower positive affect 
ratings compared to females (Goodyear et al., 2018). The negative impacts of stigmatizing 
language specific to patients were found within Antoniou et al. (2019) study to investigate 
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individuals who use opioids, as they discussed that being labelled ‘addicts’ created problems 
when seeking health care, including feeling increasingly ostracized from physicians. These 
findings reinforce the important changes made to the terminology of the DSM-V. 
Public Stigma 
Public stigma toward OUD remains prevalent, as indicated by multiple studies, and was 
portrayed by reports including public, physician and patient populations. In a nationally 
representative sample of the American general public, Kennedy-Hendricks et al. (2017) 
identified respondents expressed high levels of stigma towards individuals with prescription 
OUD, a desire for social distance, and felt employers should be allowed to deny employment to 
persons with prescription OUD. Additionally, large majorities of this sample felt individuals with 
prescription OUD are to blame for the problem (78%) and lacked self-discipline to use 
prescription opioids without become ‘addicted’ (72%) (Kennedy-Hendricks et al., 2017). A 
public perception that prescription OUD predominantly affects persons with low income was 
also associated with a greater likelihood of believing persons with prescription OUD are 
dangerous and to blame for the problem (Kennedy-Hendricks et al., 2017). This study also 
concluded higher stigma ratings were associated with lower support for public health orientated 
policies, including to expand coverage of prescription OUD treatment (Kennedy-Hendricks et 
al., 2017).  
Goodyear et al. (2018) employed a vignette survey to better understand public perception 
of opioid use revealing higher stigmatizing attitudes towards an individual who took opioids 
from a friend, compared to an individual who received a prescription opioid from a doctor. This 
may speak to the implications of public stigma as it relates to the opioid crisis, as individuals 
may tend to hide their opioid use due to these negative attitudes. Physician respondents from 
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Livingston et al. (2018) study expressed concern about methadone prescribing due to a local 
history of negative media coverage regarding physicians’ opioid prescribing practices. Their 
responses gave a sense of general uneasiness due to publicized and politicized opioid related 
deaths, with one stating there is a “large public concern… large concern from law 
enforcement…” (Livingston et al., 2018, p. 350). This was related to contextual factors of 
community opposition to methadone being provided at primary care clinics, with respondents 
reporting a “not in my backyard mentality” (Livingston et al., 2018, p. 350). Further, within the 
USA, Tsai et al. (2019) recognized that news coverage largely frames the opioid crisis as a 
criminal justice issue, which further promotes public stigma and misunderstanding of OUD as a 
health issue. Tsai et al. (2019) recognized that the continued use of stigmatizing language is 
capable to foster further public stigma and promotes lack of public support for public health-
oriented policies.  
Opioid Use Familiarity 
Many of the studies alluded to the contact hypothesis that people who have more contact 
or experience with a stigmatized condition are therefore more tolerant and have more positive 
attitudes towards these people (van Boekel et al., 2013). This was evident in Goodyear et al. 
(2018) vignette study of a large sample of the American public, which found that participants’ 
past or current opioid use may influence their stigmatizing attitudes towards someone with an 
opioid use condition. Additionally, van Boekel et al.’s (2013) review found that professionals 
who more frequently work with or who have more contact with patients with substance use 
disorders expressed more positive attitudes. Two studies from their literature analysis revealed 
that health professionals who were more frequently in contact with people who use injection 
drugs expressed more positive explicit attitudes towards these people (van Boekel et al., 2013). 
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These findings were further validated in the study by Livingston et al. (2018) as physician 
respondents who were methadone prescribers at time of data collection described providing OAT 
as interesting and enjoyable practice or as fulfillment of their professional duty to reduce 
suffering (Livingston et al., 2018). Further, in one study identified by van Boekel et al. (2013), 
physicians with a personal experience or history of a substance use disorder reported more 
positive attitudes towards patients suffering similar problems.  
Conversely, one study employed a public opinion survey which displayed attitudes that 
were similar among those with and without personal experience of OUD, providing little 
evidence that personal experience reduces stigma (Kennedy-Hendricks et al., 2017). The authors 
did note that some respondents who had personal experience with OUD expressed higher levels 
of stigma on some measures, which they suggested may be due to strained interpersonal 
relationships for individuals with OUD that heighten stigma among friends and family 
(Kennedy-Hendricks et al., 2017). 
Stigma and Opioid Policy 
 Stigma plays an important role for support and implementation of policies that relate to 
opioid use and the opioid crisis. This was evident across study populations involving the public, 
patients and health care providers. A public opinion survey in the USA indicated higher levels of 
stigma were independently associated with greater public support for punitive policies and lower 
support for public health-oriented policies (Kennedy-Hendricks et al., 2017). The authors 
verified this data should not be interpreted as causal due to a potential policy feedback loop: 
although punitive drug policies may be a result of stigma, these policies also intensify negative 
attitudes as they define the affected population as criminals (Kennedy-Hendricks et al., 2017). 
Nevertheless, these findings promote the notion that reducing stigma towards individuals with 
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prescription OUD may be one way to discourage the adoption of further punitive policies 
(Kennedy-Hendricks et al., 2017). As the study was completed with participants solely from the 
USA, these results may not be entirely applicable to the general public of British Columbia; 
however, the opioid crisis has significant detriments amongst both American and Canadian 
populations, and for that reason these outcomes may be applicable.  
Antoniou et al. (2019) investigated patients in their study to characterize individual 
impacts of implemented opioid related policies and harm reduction interventions in Ontario that 
were implemented in response to the rise in opioid related deaths. Patients who used prescription 
opioids from urban, suburban and rural areas provided qualitative data that allowed the authors 
to conclude that an experience of deepening of stigma had occurred, particularly during 
encounters with health care providers; one participant explained “…my doctors… scared 
because of current policies? You darn well bet… when I go to the ER I get shunned, like they are 
terrified of me and why?” (Antoniou et al., 2019, p. 18). These changes also indicated a loss of 
autonomy for patients with a curtailed ability to engage in shared decision making with 
providers, manifesting as mistrust, suspicion and disrespect in the patient-provider relationship 
(Antoniou et al., 2019). Patients characterized a sense of powerlessness associated with a 
perceived unilateral transfer of responsibility for the overprescribing of opioids from clinicians to 
patients (Antoniou et al., 2019). One participant described this as “…now you have got me 
hooked on them and you can’t give me any” (Antoniou et al., 2019, p. 18) which speaks to the 
unintended consequences of deprescribing of opioids across Canada and is applicable to the 
context in British Columbia. Furthermore, impacts of the new opioid policies exacerbated 
vulnerabilities experienced by patients who take prescribed opioids due to deteriorations of pain 
control, and mental health that, for some, resulted in unemployment and lack of health insurance 
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(Antoniou et al., 2019). The authors recognize these experiences exemplify that stigma is closely 
related to a power differential as those with control over social, economic and political capital 
are favourably positioned to allow the consequences of stigma and discriminatory processes to 
unfold (Antoniou et al., 2019). This is also pertinent to the setting of British Columbia as 
morbidity and mortality related to OUD remain elevated, despite the implementation of these 
policies in response to the opioid crisis.  
Amongst health care providers, some respondents related that punitive measures 
enhanced complexities associated with caring for patients with OUD as “sometimes they’re in 
and out of jail too, which makes things challenging” (Livingston et al., 2018, p. 349). Additional 
hesitations from primary care provider respondents were articulated regarding the potential 
disciplinary actions associated with patients suffering with OUD: “it opens you up having to go 
to court” (Louie et al., 2019, p. 5). Tsai et al., (2019) related stigma’s impacts on policy to health 
disparity populations, as few incarcerated or recently released individuals receive treatment or 
are linked to treatment, which is a significant missed public health opportunity. Further, these 
authors recommend that the judicious use of stigmatizing language influences the norms about 
OUD among policymakers and constituents, with effects on policy levers that directly impact the 
government’s response to the opioid crisis (Tsai et al., 2019). For example, the pejorative use of 
‘substance abuser’ or devaluing evidence-based treatments has influence on supportive policy 
development.  
Mitigation of Researcher Bias 
 An effort to maintain transparency of the methods and process of the review has been 
made throughout this paper to decrease risk of bias; however, all considerations of introducing 
and mitigating bias must be discussed (Whittemore & Knafl, 2005). As bias and error may occur 
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at any stage of the review, identification of the potential for partiality will be addressed in the 
following portion of the paper (Whittemore & Knafl, 2005). 
Acknowledgement of Researcher Bias 
 To promote the transparency and quality of the presented findings in this integrated 
literature review, acknowledging the risk of researcher bias will be presented here. Given that I 
am this paper’s sole author and conducted the interpretation of the data alone, acknowledging my 
own reporting bias remains necessary. The risk of a bias assessment may impact the credibility 
of the research; as such, reviewing my personal preconceptions regarding the topic is important 
so that they are not imposed on the findings and to maintain neutrality. 
I am aware of my own privilege as a person who comes from a well-resourced 
background and no personal history of OUD, nor have I experienced anyone close to me reveal 
their own struggle with OUD. Within my personal career as a registered nurse for nine years, I 
have encountered several patients with varying substance use disorders. My most recent work as 
a registered nurse was in a critical care area in a large, downtown hospital in Vancouver, British 
Columbia, which has often been referred to as the ‘epicenter’ of the ongoing opioid crisis. I spent 
much of my last two years within the post anaesthetic care unit and, for this reason, I am very 
familiar with administering opioids and have had multiple patient encounters with individuals 
suffering with OUD and complex pain management. I have witnessed the enduring stigma 
present in health care settings from colleagues as well as amongst individuals outside health care 
settings. In the past I have encountered a colleague unable to independently administer opioids 
due to a history of opioid misuse and varying levels of stigma were evident amongst my peers in 
response to this situation. My exposure and experiences with opioids and patients with OUD 
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have ultimately impacted my preconceptions about what the research would say and the 
conclusions I have drawn from the literature. 
 I pursued this research as I sought to understand the concept of stigma and how it is 
fundamentally undermining the responses to the opioid crisis in British Columbia. As an entry 
level primary care provider candidate, I wanted to ensure that upon entering practice I prevented 
myself from perpetuating further stigma as well as inappropriate opioid prescribing. I was 
unaware of the vast implications of stigma, how it is experienced by those it affects, and the 
multifactorial origins. Conducting this literature review has allowed me to examine my own 
inherent biases regarding providing care for patients with OUD and the opioid crisis in British 
Columbia. Identification and awareness of these assumptions are essential aspect of a competent 
inquiry to ensure objective examination of the data (Creswell & Creswell, 2018). Additionally, I 
employed research reflexivity by reflecting on my role and personal background as they may 
shape my interpretation of the data (Creswell & Creswell, 2018). Within the entirety of the 
paper, efforts to use clear, straightforward, unbiased language were made to ensure that my 
writing does not bestow stigmatizing or insensitive connotations. To enhance validity of the 
findings and further mitigate a biased assessment, thick, rich descriptions from study participants 
and disconfirming evidence were also included (Creswell & Creswell, 2018). Additionally, the 
process of choosing a variety of literature sources for examination enables triangulation of the 
data, by identifying themes that are established based on converging evidence, which further 
enhances the validity and objectivity of my research (Creswell & Creswell, 2018). The 
conclusions I have depicted from the integrative literature review are presented in the following 
section of the paper.  
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Chapter V: Discussion  
 
This section of the integrated literature review in the final step of the process and will 
discuss the conclusions I have drawn from the review. I will provide recommendations for 
primary care providers to implement in practice and finally the limitations of the literature 
sample will be presented. 
Synthesis of Findings 
 
Findings from this integrative literature review demonstrate the powerful phenomenon of 
stigma and the extensive effects it can have on its targets. For individuals with OUD, stigma 
stems from several sources and continues to exist as a complex interplay of how these stigmas 
intersect, ultimately generating social exclusion and a myriad of negative health consequences. 
Importantly, the results illustrate several areas that primary care providers are well positioned to 
diminish the persistent and intertwined stigma toward individuals with OUD that may ultimately 
improve outcomes at individual as well as population levels.  
The prevalent sentiment of professional stigma found within the review toward 
individuals with OUD is an area of particular concern that can certainly be addressed by primary 
care providers (Kennedy-Hendricks et al., 2016; Louie et al., 2019; van Boekel et al., 2013; 
Deflavio et al., 2015; Livingston et al., 2018). Discrimination and mistrust seemed to coalesce 
amongst participants expressing professional stigma, with views that individuals with OUD 
differ from other patient populations, as this particular diagnosis gives the impression of being 
unusual and beyond the skillset of primary care providers (Livingston et al., 2018; Louie et al., 
2019; van Boekel et al., 2013). The adverse view shared by providers within the literature sample 
may be attributed to consistent negative narratives surrounding opioids amongst peers, the 
public, and regulatory bodies which may foster misjudgement or overstating the challenges of 
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caring for patients with OUD, especially for those with minimal first-hand experience 
(Livingston et al., 2018; van Boekel et al., 2013). This finding is convergent with the themes of 
insufficient education and opioid familiarity, as amongst providers who excluded patients with 
OUD in their practice or who were non-OAT prescribers or were new to practice, and these 
groups were more likely to refer to patients with OUD as inappropriate for primary care due to 
their difficult and challenging needs (Deflavio et al.; 2015; Livingston et al., 2018; Louie et al., 
2019). The relevant theory that increased contact with stigmatized populations can improve 
attitudes was upheld by a subgroup of providers who provided care for patients with OUD and 
were OAT prescribers, as they reported their patient interactions as mostly straightforward and in 
some cases rewarding (Goodyear et al., 2018; Livingston et al., 2018; Louie et al; 2019). 
Additionally, this may also be relative to their encounters with patients who are stable on OAT, 
versus the interactions of non-prescribers are likely with individuals who are not stable on OAT, 
and therefore a considerable variant of patient presentations occurs. As a result, the patients 
encountered by non-prescribers may be more likely to be in a state of withdrawal and in need 
treatment; further validating the necessity of increasing access to appropriate care for patients 
struggling with OUD.  
The skepticism, hesitancy and lack of interest of primary care providers to provide OAT 
defeats a main component of the comprehensive care plan for patients with OUD in British 
Columbia. Professional stigma towards OAT portrays it as an unconventional therapy, discredits 
prescribers’ practices as well as substantiates the stigma towards patients who use OAT. This 
enforces barriers to access care due to lack of OAT prescribers, decreasing engagement and 
adherence to OAT, while promoting public stigma associated with OAT and support of harm 
reduction activities to exist within primary care practices (Livingston et al.; 2018; Louie et al., 
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2019). Once again, this stigma can be attributed to insufficient knowledge and lack of skills that 
can be addressed by engaging current and future providers in appropriate avenues of education 
and mentorship (Deflavio et al., 2015; Louie et al., 2019). 
Professional stigma has continued to evolve within an environment where individuals 
who use opioids or suffer from OUD are essentially characterized as patients who do not belong 
to primary care, disqualifying their social status, and revealing a dominant attitude of 
“undeserving addict” (Antoniou et al., 2019, p. 19). The notion of these patients as abnormal and 
inappropriate to primary care settings is unacceptable within British Columbia, especially given 
the current climate of an escalating opioid crisis. This can absolved through employing stigma 
interventions in primary health care settings, increasing knowledge and training of current 
primary care providers, providing essential education specific to OUD in medical school and 
nurse practitioner programs, while acknowledging the professional and ethical responsibilities 
primary care providers are upheld to (Deflavio et al., 2015; Khenti et al., 2019; Livingston et al., 
2018; Louie et al., 2019). Utilizing a trauma informed approach and recognizing individuals’ 
unique identities during care provision will destigmatize the dominant ‘addict’ social identity 
that has taken over for individuals who use opioids, while promoting a therapeutic patient-
provider relationship to ensure these vulnerable patients are included within primary health care 
settings of British Columbia (Antoniou et al., 2019). Further, primary care providers must ensure 
that their care remains empathetic, compassionate, patient centered and collaborative amongst 
the population of patients with OUD to promote trust, diminish power imbalances and improve 
engagement and retention in care (Antoniou et al., 2019; van Boekel et al., 2013).  
The perceived and internalized stigma experienced by individuals with OUD is 
discouraging care seeking behaviours, negatively affecting their treatment outcomes, and is 
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associated with greater engagement high risk behaviours, including obtaining opioids from 
untrustworthy sources (Tsai et al., 2019). Patients are indeed capable of perceiving the 
discriminatory and conflict laden nature of primary care providers, internalizing the negative 
stereotypes bestowed upon them, which discourages seeking help when they need it most 
(Antoniou et al., 2019; Kulesza et al., 2017). Further, it seems the mistrust, stereotyping and 
paternalistic treatment from providers, perpetuates patients’ mistrust of the health care system 
and therefore a lack of therapeutic alliance withstands between this patient population and 
providers. Shared and informed decision making that incorporates patient preferences and values 
will improve collaboration, empower patients, promote continuity of care while decreasing 
stigma for patients to access primary care services for OUD (Antoniou et al., 2019). 
Including individuals who have abstained from opioid use or who are stable on OAT for 
some specified period of time, also known as peers, may help to facilitate engagement and 
retention in primary care for individuals who use opioids or have OUD and may also provide 
beneficial support and opioid use familiarity for health professionals within a primary care 
setting. Successful integration of peers endorses trust, demotes discrimination, values social 
identities, empowers patients’ prospects of recovery, and appreciates lived experiences 
(Antoniou et al., 2019). This will assist to diminish professional stigma, promote fairness in 
access to care, while supporting patients to ensure they feel safe and welcomed to seek help for 
opioid use, and may also conceivably discourage individuals from hiding their opioid use. 
Incorporating peers within primary health care also encourages their inclusion amongst members 
of the general public, decreasing the marginalization and stereotyping of people who use opioids. 
Further, increased peer involvement in health care will foster their meaningful presence in the 
formulation and implementation of future policies, avoiding further unintended consequences. 
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As gate keepers within the healthcare system and frequent interactions with people from 
all walks of life, primary care providers set a precedent for how individuals with OUD are 
portrayed amongst colleagues, patients, members of the public, constituents and policy makers. 
Their use of proper terminology will help to reframe the way patients with OUD are thought 
about and described; a key component to reduce stigma, discrimination, mistrust and the 
reluctance of these individuals to access the health care system. This involves primary care 
providers prohibiting the use of stigmatizing language day-to-day in verbal communication, 
clinical documentation, as well as the use of printed materials that may be distributed from 
clinical settings. Utilizing the term OUD promotes clinical terminology and can improve public 
and decision maker perceptions, while the use of other pejorative language is associated with 
greater individual responsibility, voluntary behaviour, control over behaviour and supports 
punitive judgements (Goodyear et al., 2018; Kennedy-Hendricks et al., 2017; Tsai et al.; 2019). 
The use of non-stigmatizing language humanizes this medical condition and supports 
implementation of unbiased and effective policy (Tsai et al., 2019). Further, appropriate use of 
language is vital to diminish public stigma, as the public influence the structural elements of 
transforming laws and policies (Tsai et al., 2019). In addition, public stigma may also impact a 
primary care provider’s decision making regarding the implementation of prescribing OAT, 
especially in rural and remote settings (Tsai et al., 2019; Livingston et al.; 2018). For these 
reasons, primary care providers must identify and take action to eradicate the multiple sources of 
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Recommendations  
A table was utilized to display the recommendations for primary care providers to 
implement in their practice to reduce stigma. Each recommendation is listed beside their 
corresponding source of stigma along with specific strategies to implement in the primary health 
care setting in Table 2 below.  
Table 2 
 
Sources of Stigma and Recommendations for Diminishing Stigma in Practice for Patients with 















welcoming care for 
patients with OUD 
as a standard of 
primary health care 
practice 
• Include and welcome 
patients with OUD or 
hx of OUD in primary 
care clinic setting 
• Ensure empathetic, 
trauma informed 
approach utilized for 
patient care interactions 
• Listen to patients’ 
stories, appreciate their 
values, preferences and 
individuality during 
interactions to promote 
trusting relationship 
• Empower patients by 




include peers with 
OUD or hx of OUD in 
primary health care 
setting 
• Ensure to allot 
appropriate time for 
appointments for 
patients with OUD 
(Antoniou et al., 
2019; Goodyear 
et al., 2018; 
Kennedy-
Hendricks et al., 
2016; Khenti et 
al., 2019; 
Kulesza et al., 
2017; Livingston 
et al., 2018; Tsai 
et al., 2019; van 
Boekel et al., 
2013) 




Recommendation Strategies in the Primary 
Care Setting 
References 
• Describe and 
acknowledge OUD as a 
chronic, relapsing, 
complex clinical 
disorder associated with 
several risk factors and 
extrinsic variables 
• Recognize patients 
accessing primary care 
as an opportunity to 
address social 
determinants of health  
• Use ‘people first 
language’ to describe 
patients in any verbal 
communication or in 
clinical documentation 
• Employ education to 




team members at 
primary care setting 
• Screen all patients for 
opioid use or OUD 
when appropriate or 
indicated 
• Provide alternate 
provider in event 
unable to provide 
appropriate care for 
patient with OUD 
• Identify a professional 
colleague mentor who 
provides care for 
patients with OUD  
• Acknowledge and 
adhere to professional 
responsibilities and 
codes of ethics 














Prescribe OAT as 
an evidence-based 
treatment for OUD 
• Complete education 
and training to 
prescribe OAT through 
BCCSU 
• Prescribe OAT for mild 
to moderate cases of 
OUD 
• Educate patients with 
OUD about different 
OAT options 
• Acknowledge OAT as 
effective, evidence-
based treatment for 
OUD 
• Meet patients where 
they are at in their 
journey, when they feel 
ready to implement 
OAT or reattempt 
implementing OAT 
• Seek substance use 
specialist 
guidance/support for 
complex cases of OUD, 
or refer to substance 
use specialist if 
indicated for severe 
cases 
• Identify a colleague 
mentor who is OAT 
prescriber for support 
(Deflavio et al., 
2015; Livingston 
et al., 2018; 
Louie et al., 








with OUD as 
having a complex, 
chronic medical 
condition  
• Complete education 
and preceptorship 
regarding OUD and 
OAT through BCCSU  
• Review DSM V criteria 
for OUD diagnosis 
• Encourage colleagues 
belonging to your 
primary care practice to 
complete modules from 
BCCSU 
(Deflavio et al., 
2015; Khenti et 
al., 2019; 
Livingston et al., 
2018; Louie et 
al., 2019; van 
Boekel et al., 
2013) 




Recommendation Strategies in the Primary 
Care Setting 
References 
• Promote education 
regarding OUD as a 
necessity in training of 
future physicians, nurse 
practitioners and other 
health professionals 
• Ensure up to date 
guidelines for OUD 
accessible and available 
to all providers at 










patients who have 
OUD 
• Welcome patients with 
OUD to your primary 
care practice setting 
wherever they may be 
in their journey in non-
judgemental manner 
• Ensure to practice 
inclusive, culturally 
safe, trauma informed 
and patient centered 
care 
• Recognize patients’ 
unique identities and 
cultures rather than 
allow OUD to define 
them 
• Employ ‘people first 
language’ 
• Encourage patients to 
have opinions, express 
their feelings and 
preferences during care 
decisions 
• Provide choices for 




• Include peer integration 
into primary health care 
for patients with OUD 
(Antoniou et al., 
2019; Kulesza et 
al., 2017; Tsai et 
al., 2019) 




Recommendation Strategies in the Primary 
Care Setting 
References 
• Draw on approaches 
from cognitive 
behavioral therapy for 




Use ‘person first 
language’ to 
describe patients 
with OUD or 
people who use 
drugs 
• Use ‘person first 
language’ in day to day 
life in clinical settings 
for verbal 
communication and 
clinical documentation  
•  Use ‘person first 
language’ outside 
clinical setting 
• Review DSM-V change 
in diagnostic 
terminology 
• Use the following 
terminology: Opioid 
use disorder, opioid 
use, people who use 
drugs, opioid agonist 
treatment, opioid crisis, 
positive/negative urine 
toxicology screen, 
unregulated drug use, 
unregulated drug 
supply 
• DO NOT use the 
following terminology: 
opioid abuser, opioid 
addict, opioid 






urine screen, illicit drug 
use, problematic drug 
use 
• Politely intervene when 
confronted with 
(Antoniou et al., 
2019; Goodyear 
et al., 2018; 
Livingston et al., 
2018; Tsai et al., 
2019 








and rephrase feedback  





• Recognize leadership 
role of being a primary 
care provider; include 
patients with OUD in 
practice and prohibit 
personal stigma as this 
translates to the 
community and the 
media 
• Thoughtfully intervene 
to address others’ 
stigmatizing attitudes 
and language in and out 
of primary care setting- 
“I think there may be a 
better way to describe 
the person you are 
talking about to respect 
their humanity. Calling 
them a drug addict may 
have several negative 
consequences that you 
don’t actually intend. A 
better choice in the 
future is to say the 
individual is suffering 
from an OUD” 
• Critically evaluate 
media coverage of 
opioid crisis 
(Goodyear et al., 
2018; Kennedy-
Hendricks et al., 
2017; Livingston 
et al., 2018; Tsai 




to individuals with 
OUD by including 
them in primary 
care practice 
• Include patients with 
OUD in patient panel 
• Review and understand 
pharmacology of 
opioids and OAT: 
mechanism of action, 
adverse reactions 
• Complete 2-day 
preceptorship with 
BCCSU to increase 
(Antoniou et al., 
2019; Deflavio et 
al., 2015; 
Goodyear et al., 
2018; Livingston 
et al., 2018; Tsai 
et al., 2019) 




Recommendation Strategies in the Primary 
Care Setting 
References 
exposure to patients 
with OUD 
• Acknowledge 
multifaceted cause of 
opioid crisis in British 
Columbia 





consequences of opioid 
deprescribing 
• Consider integrating 
substance use specialist 
in primary care setting 
to increase knowledge 











patients with OUD 
• Encourage meaningful 
inclusion of patients 
with OUD when 
formulating or 
implementing policy 
that may impact their 
lives 




individuals who have 
been receiving opioids 
for many years 
• Prevent power 
imbalance between 




• Respect and include 
patients in all decision 
making, especially with 
regards to opioid 
(Antoniou et al., 
2019; Kennedy-
Hendricks et al., 
2017; Livingston 
et al., 2018; Tsai 
et al., 2019) 




Recommendation Strategies in the Primary 
Care Setting 
References 
tapering or transitioning 
to OAT 
• Acknowledge patients 
with OUD as needing 
care for their health-
related issue and 
acknowledge 
importance of essential 
public health-oriented 
policies/programs 
• Maintain awareness of 
current unregulated 
drug supply 
contamination and rates 




advocate for patients 
with OUD and people 
who use opioids within 
leadership role as 
primary care provider 
during interactions with 
decision makers  
• Ensure to use non 
stigmatizing language 
during communications 
with media, policy 
makers and constituents 
 
Limitations 
 Social scientists who study stigma and stigmatized groups are often “from the vantage 
point of theories that are uninformed by the lived experience of the people they study” (Link & 
Phelan, 2001, p. 365). This is a relevant limitation applicable to this review, as the researchers of 
the included studies do not belong to a stigmatized group, nor do I, and for that reason, the 
outcomes may be a misinterpretation of the experience of those who are stigmatized, further 
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perpetuating unsubstantiated assumptions (Link & Phelan, 2001). Accordingly, the most fitting 
evidence to inform the findings would likely involve a majority of patient participants and their 
experiences of stigma; however, the literature search only resulted two applicable primary 
studies (n=2) (Antoniou et al., 2019; Kulesza et al., 2017) comprising patient respondents. 
However, it is encouraging many authors were in agreement that future research should focus on 
individuals who experience stigma to gain an improved understanding of the negative 
repercussions, making it seem likely a similar literature search in the near future may generate 
more lived experiences of stigma as it relates to individuals with OUD (Antoniou et al., 2019; 
Goodyear et al., 2018; Kulesza et al.; 2017; van Boekel et al., 2013).  
A specific limitation recognized by Kulesza et al. (2017) in their study of patient 
participants, was that the research was conducted at a clinic serving an underprivileged 
community, which may decrease the generalizability of the results to general primary care 
populations. Conversely, the study may be applicable to the context of primary health care in 
British Columbia as the authors recognized this population was also racially and ethnically 
diverse (Kulesza et al., 2017). In regard to the Canadian study involving patient participants, it is 
unclear if the sample was representative of all individuals who use opioids, as the participants 
belonged to specialized clinics and community centers, decreasing the external validity within 
the primary care setting (Antoniou et al., 2019). However, this study was relevant to include as it 
provided individual, qualitative patient accounts in response to the consequences of the opioid 
policies implemented across Canada in 2017 (Antoniou et al., 2019).  
Another limitation identified within the literature sample was van Boekel, Brouwers, van 
Weeghel and Garrtesen’s (2013) systematic review involved studies of health professionals’ 
attitudes that were non-specific to OUD. The participants in these results included physicians, 
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nurses and other health care workers; as such these results may not be entirely generalizable to 
the primary care provider context in British Columbia. Nevertheless, the negative attitudes of 
these health professionals resulted in a lack of empathy and an avoidant approach, which the 
authors indicated may have negative impacts on treatment outcomes, patients’ self-esteem and 
ultimately the delivery of suboptimal healthcare (van Boekel et al., 2013). Further, discernment 
of studies regarding illegal drug use were present, but there were no studies included specific to 
OUD or primary care providers which may decrease the external validity to the current climate 
in British Columbia. Nevertheless, the findings did represent the similar conclusions of other 
included studies, that generally health professionals have negative attitudes towards patients with 
substance use disorders.  
As this integrative literature review was completed to inform primary care providers 
practicing in British Columbia, another relevant limitation of the literature sample was that only 
three studies were conducted in Canada and all originated from Eastern provinces, Ontario (n=2) 
(Antoniou et al., 2019; Khenti et al., 2019) and Nova Scotia (n=1) (Livingston et al., 2018), 
decreasing the external validity. The other five primary studies and three secondary sources 
originated in the USA. While the results from these studies can be considered in the context to 
reduce stigma within primary care practice in British Columbia, the exact accounts of stigma as 
it is experienced by patients and portrayed by professionals cannot be made exclusively on this 
research. Further, the explanations of stigma as it relates to primary care providers, the general 
public, and local policy from this review may not be entirely applicable to the current evolving 
health, social and political climate of British Columbia.   
It has been recognized as a challenge to study stigma by researchers for several reasons. 
Within the evidence there is a general acknowledgement of a need for more indirect 
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measurement procedures to inform the evidence as well as the need to conceptualize stigma with 
less of an individualistic focus as this can lead to harmful outcomes (Kulesza et al., 2017; 
Goodyear et al., 2018; Yang et al., 2019). This is evidenced by past inquiries about living with a 
disability because the research has been uninformed by the lived experience of the people 
experiencing the disability, with experts giving priority to the scientific theories and research 
techniques utilized (Link & Phelan, 2001). Another limitation that may contribute to erroneous 
data related to stigma investigation is the case when self-report measures are employed to 
understand opinions or attitudes pertaining to OUD. This may have been the case in the study by 
Kulesza et al. (2017) that utilized the validated Substance Abuse Stigma Scale tool, as the 
reporting individuals were likely aware of discriminatory responses and the data collection may 
have been influenced by their own social desirability concerns. Additionally, the use of 
stigmatizing terminology within the tool itself may generate an implicit bias, as previously 
mentioned in the findings. For these reasons the full power and significance of internalized 
stigma as it relates to patients with OUD and health outcomes remains somewhat obscured. 
Future Directions  
The study of stigma as it relates to OUD is best conveyed by phenomenology which 
seeks to know the essence of the phenomenon experienced and what does it mean (Reed & 
Crawford Shearer, 2018). This investigation involves analysis of the subjective phenomena to 
understand the truths about reality grounded within individuals who have lived experiences of 
stigma (Reed & Crawford Shearer, 2018). This work is typically completed with small samples, 
which is applicable to future studies that are more specific to consider culture and disease 
separately in an effort to make statements about the essential truths based on the common 
categories of lived experiences of those who are stigmatized (Reed & Crawford Shearer, 2018). 
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Additionally, research on stigma comes from multiple disciplines regarding how stigma operates 
and induces harm on varying populations, yet progress to tackle stigma and its harmful 
consequences is lacking. Collaborative efforts are required to move forward across disciplines, 
standardize measures, and build more effective interventions for clinicians in practice, including 
how to measure changes for specific outcomes over time (Stangl et al., 2019; Tsai et al., 2019).  
Future research to address stigma as it relates to individuals with OUD should seek to 
determine the experiences stigma related to prescription OUD separately from illegal supply 
OUD, as a variance in negative attitudes towards these disorders exists and may resultingly cause 
these populations to suffer unique stigma related health disparities. Additionally, future research 
on primary care provider attitudes and patient perceptions should be assessed using longitudinal 
study designs to determine the effects and consequences of stigma over time. This would method 
would allow for evaluation of the effectiveness of interventions such as education 
implementation, anti-stigma campaigns, and standardized OAT prescribing in primary health 
care practices of British Columbia. Evaluations of efficacious stigma interventions would also be 
valuable to examine patients for greater emotional well-being and higher quality of life (Kulesza 
et al., 2017). Exploring the manner in which the social determinants of health, policy and stigma 
intersect may also be beneficial to understand of the vast outcomes policy implementation has 
amongst individuals with OUD (Goodyear et al., 2018; Antoniou et al., 2019). More explorations 
are needed to understand the causal pathways through which stigma acts so that targeted 
interventions can be deployed to enhance the response to care for patients with OUD and 
improve responses to the opioid overdose crisis.   
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Chapter VI: Conclusion  
The current role of primary care providers in British Columbia is often to provide care for 
patients who have complex care needs, and this must include individuals who suffer from OUD. 
The elimination of stigma in primary health care settings of British Columbia is essential to 
improve equitable access, ensure quality of care and promote healing for individuals with OUD. 
The sources of stigma particular to this population are complex and intersecting; primary care 
providers are well positioned to address these intricacies by ensuring primary health care is an 
inclusive, trusting, collaborative and non-discriminatory environment supportive of evidence-
based treatments (Antoniou et al., 2019; Tsai et al., 2019). OUD has significant economic, 
personal and public health consequences, and primary care providers are also capable of 
expanding consistent access to timely services across the province that are ready and responsive, 
promoting effective and safe care while helping to evenly distribute the responsibility of care 
during the opioid crisis. Further, they must be cognizant of their unique position to be agents for 
change and exemplars by only using ‘people first language’ when communicating about 
individuals with OUD to eliminate persistent stigma amongst the public and decision makers 
(Kelly et al., 2016; Tsai et al., 2019). 
The ongoing opioid overdose crisis in British Columbia substantiates the necessity to 
destigmatize and expand access to essential care for OUD to improve effective management of 
this chronic disease. Timely efforts to address this health and social issue are critical as untreated 
OUD remains one of the major drivers of the present opioid overdose crisis (Tyndall, 2018). 
Efforts of primary care providers to diminish stigma are instrumental and will positively impact 
the comprehensive care that patients suffering OUD receive and address the ongoing overdose 
crisis. Until the stigma of OUD and opioid use is defied, it will continue to hinder 
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implementation of interventions and the responses to the opioid crisis, exacerbating the health 
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Appendix A 
 
DSM-5 Criteria for Diagnosis of Opioid Use Disorder 
 
1. Opioids are often taken in larger amounts or over a longer period than what was intended 
2. There is persistent desire or unsuccessful efforts to cut down or control opioid use 
3. A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, or 
recover from its effects 
4. Craving or strong desire to use opioids 
5. Recurrent opioid use resulting in a failure to fulfill major role obligations at work, school 
or home 
6. Continued opioid use despite having persistent or recurrent social or interpersonal 
problems caused or exacerbated by the effects of opioids 
7. Important social, occupational, or recreational activities are given up or reduced because 
of opioid use 
8. Recurrent opioid use in situations in which it is physically hazardous 
9. Continued use despite knowledge of having persistent or recurrent physical or 
psychological problem that is likely to have been caused or exacerbated by opioids. 
10. Tolerance*, as defined by either of the following: 
a. Need for markedly increased amounts of opioids to achieve intoxication or 
desired effect 
b. Markedly diminished effect with continuous use of same amount of opioid 
11. Withdrawal*, as defined by either of the following: 
a. Characteristic opioid withdrawal syndrome 
b. Same (or closely related) substance is taken to relieve or avoid withdrawal 
symptoms 
 
The presence of at least 2 of these symptoms indicates an opioid use disorder (OUD) 
 
The severity is defined as:  
MILD: The presence of 2 to 3 symptoms 
MODERATE: The presence of 4 to 5 symptoms 
SEVERE: The presence of 6 or more symptoms 
 
*patients who are prescribed opioid medications for analgesia may exhibit these two criteria 
(withdrawal and tolerance) but would not necessarily be considered to have a substance use 
disorder. 
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Appendix B 
 
Individual Database Searches 
 
Database MeSH, non-MeSH 
Keywords and Boolean 
Operators 
Results 
CINAHL (MH ”Substance Use 
Disorders”) AND (MH 
“Analgesics, Opioid” OR  
(MH “Substance Abusers”) 
AND (MH” Analgesics, 
Opioid”) OR opioid use 
disorder OR opioid abuse OR 
opioid addiction AND (MH 
“Stigma”) OR (MH “Attitude 
to Illness”) OR (MH 
”stereotyping”) or self-stigma 
AND (MH “Primary Health 
Care”) OR primary care OR 
primary care provider 
n= 26 
Medline (MH “Opioid -Related 
Disorders) OR (MH “Opioid 
Epidemic”) OR opioid use 
disorder OR opioid abuse 
AND (MH “Social Stigma”) 
OR (MH “Prejudice”) OR 
(MH “Perception”) OR 
stigma AND (MH “Primary 
Health Care”) OR (MH 
“Physicians, Primary Care”) 
OR (MH “Primary Care 
Nursing”) 
n= 52 
PyscARTICLES opioid use disorder OR 
opioid abuse OR opioid 
addiction AND stigma OR 
attitudes 
n= 3 
PsycINFO opioid use disorder OR 
opioid abuse OR opioid 
addiction AND stigma OR 
attitudes OR perception AND 
primary care OR primary 
health care OR primary care 
OR primary care provider 
n= 132 
Pub Med opioid use disorder OR 
opioid abuse OR opioid 
n= 64 
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Database MeSH, non-MeSH 
Keywords and Boolean 
Operators 
Results 
addiction AND stigma AND 
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Appendix C 
From the original non-duplicate records selected for review (n=196), 11 met the criteria for 




































Records After Duplicates Removed (n= 196) 
Records Screened: 
 (n=167) 
Records Excluded  
(n= 133) 
Full text articles assessed 
for eligibility (n=34) 
Secondary sources included in 
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